SYSTEMS AND METHODS FOR THE DETECTION OF INFECTIOUS DISEASES

Information

  • Patent Application
  • 20220325324
  • Publication Number
    20220325324
  • Date Filed
    May 16, 2022
    2 years ago
  • Date Published
    October 13, 2022
    a year ago
Abstract
The present invention relates to method of detecting and characterizing one or more Borrelia species causing Lyme Disease or tick-borne relapsing fever within a sample from a subject, the method comprising: a) subjecting DNA and/or RNA from the sample to a PCR amplification reaction using primer pairs targeting at least one region of Borrelia 16S rRNA and at least one region of flaB, ospA, ospB, ospC, glpQ, 16S-23S intergenic spacer (IGS1), 5S-23S intergenic spacer (IGS2), bbk32, dbpA, dbpB, and/or p66; and b) analyzing amplification products resulting from the PCR amplification reaction to detect the one or more Borrelia species.
Description
REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

The official copy of the sequence listing is submitted electronically via EFS-Web as an ASCII-formatted sequence listing with a file named “91482_201_Sequence_Listing.txt” created on Feb. 9, 2017, and having a size of 85 kilobytes, and is filed concurrently with the specification. The sequence listing contained in this ASCII-formatted document is part of the specification and is herein incorporated by reference in its entirety.


TECHNICAL FIELD

The present invention relates to the field of detection of Borrelia species that cause Lyme Disease and tick-borne relapsing fever in samples from a subject.


BACKGROUND

Lyme disease, also known as Lyme borreliosis, is caused by infection with the bacterial spirochete Borrelia burgdorferi, which is transmitted by the bite of Ixodes ticks. Borrelia burgdorferi, Borrelia garinii and Borrelia afzelii cause Lyme disease in Eurasia and Borrelia burgdorferi and Borrelia mayonii cause Lyme disease in the United States and Canada. B. garinii has been found in pelagic bird colonies off the coast of North America, so there may be potential for infection by this agent in North America. The four Lyme disease agents Borrelia burgdorferi, Borrelia mayonii, Borrelia garinii and Borrelia afzelii are referred to as Borrelia burgdorferi sensu lato, that is, “in the broad sense.” The North American genospecies Borrelia burgdorferi is called Borrelia burgdorferi sensu stricto, “in the strict sense.”


Lyme disease is characterized by three stages: 1) early localized Lyme disease; 2) early disseminated Lyme disease; and 3) late disseminated Lyme disease. A subject may be suspected of having Lyme disease where symptoms are consistent with those of Lyme disease and where an Ixodes tick bite is known or may have occurred. A characteristic rash called erythema migrans occurs in 70-80% of Lyme disease patients at the site of an infected tick bite.


Early localized Lyme disease is characterized by erythema migrans. Early disseminated Lyme disease typically occurs days to weeks after the initial bite by an infected tick and possible signs include secondary erythema migrans, early neuroborreliosis (cranial nerve palsy, meningitis, or radiculoneuropathy) or, uncommonly, Lyme carditis (atrioventricular node conduction block). Non-specific symptoms such as malaise, fever, headache, and muscle and joint pains may be present. Late disseminated Lyme disease occurs months to years after the initial bite by an infected tick. The most common manifestation of late disseminated Lyme disease in North America is Lyme arthritis, which is characterized by intermittent attacks in large joints, particularly the knees. Rarely, late neuroborreliosis develops, with manifestations including encephalopathy, encephalomyelitis, and/or peripheral neuropathy. Wormser, G. P., et al. Clin Infect Dis 2006; 43:1089-1134.


Lyme arthritis is a late manifestation of Lyme disease affecting up to 60% of untreated patients in the United States. Ten percent of patients treated with antibiotics continue to suffer from recurrent bouts of Lyme arthritis, Steere, A. C. and L. Glickstein, Nat Rev Immunol, 2004. 4(2): p. 143-52. Cartilage loss and subsequent bone destruction which are features of osteoarthritis and rheumatoid arthritis also occur in advanced cases of Lyme arthritis, Lawson, J. P. et al., Radiology, 1985, 154(1):37-43. Lyme arthritis develops when the bacteria invade joint tissue, most commonly the knee, and trigger inflammation as part of a strong host immune response. Despite this vigorous immune response, Borrelia are able to persist in joints which are thought to be a protective niche for the bacteria due to limited perfusion, Liang, F. T., et al., Am J Pathol, 2004, 165(3):977-85.


The detection and management of the disease is complicated by several factors, limiting the ability of clinical medicine to rapidly identify patients and subsequently employ appropriate therapy. Important complicating factors in the diagnosis of Lyme borreliosis infection include:

    • 1. Co-infection: Ixodes ticks may transmit multiple pathogens while taking a blood meal, which may result in co-infection and confounding symptoms and test results;
    • 2. Unspecific testing: multiple Borrelia species are now known and other unknown Borrelias likely exist, all of which may cause false positives on Lyme disease diagnostic tests; and
    • 3. Limited sensitivity: Borrelia infections result in typically low-level bacteremia, and therefore limited target material may be present in clinical samples.


      Another complicating factor is the difficulty of detecting active infection with the causative agent of Lyme disease in cases where symptoms are present long after potential exposure to infected ticks. There is a continuing need for compositions and methods for the diagnosis of Lyme disease that address these challenges to rapid detection and treatment.


SUMMARY

The present invention is directed to a method of detecting one or more Borrelia species causing Lyme Disease or tick-borne relapsing fever (TBRF) within a sample from a subject, the method comprising: a) subjecting DNA and/or RNA from the sample to a PCR amplification reaction using primer pairs targeting at least one region of Borrelia 16S rRNA and at least one region of flaB, ospA, ospB, ospC, glpQ, 16S-23S intergenic spacer (IGS1), 5S-23S intergenic spacer (IGS2), bbk32, dbpA, dbpB, and/or p66; and b) analyzing amplification products resulting from the PCR amplification reaction to detect the one or more Borrelia species.


In certain aspects, the primer pairs targeting at least one region of Borrelia 16S rRNA contain sequences selected from the group consisting of SEQ ID NOS: 1-10. In other aspects, RNA from the sample is subject to the PCR amplification reaction with the primer pairs targeting at least one region of Borrelia 16S rRNA.


In yet other aspects, the primer pairs targeting at least one region of flaB, ospA, ospB, ospC, glpQ, 16S-23S intergenic spacer (IGS), 5S-23S intergenic spacer (IGS2), bbk32, dbpA, dbpB, and/or p66 contain sequences selected from the group consisting of SEQ ID NOS: 11-48, SEQ ID NOS: 60-77, SEQ ID NOS: 97-100, and SEQ ID NOS: 219-293.


In one embodiment, the PCR amplification reaction is a multiplex amplification reaction. In another embodiment, the amplification products are analyzed by size determination with agarose gel electrophoresis.


In some embodiments, the amplification products are analyzed by next-generation sequencing (NGS) to determine the sequence of each amplification product. In one embodiment, the primer pairs comprise a universal tail sequence.


In certain aspects, the sequence of each amplification product is mapped to a reference library of known Borrelia sequences to detect the one or more Borrelia species. In other aspects, the one or more Borrelia species are selected from the group consisting of Borrelia afzelii, Borrelia americana, Borrelia andersonii, Borrelia anserina, Borrelia baltazardii, Borrelia bavariensis, Borrelia bissettii, Borrelia brasiliensis, Borrelia burgdorferi, Borrelia californiensis, Borrelia carolinensis, Borrelia caucasica, Borrelia coriaceae, Borrelia crocidurae, Borrelia dugesii, Borrelia duttonii, Borrelia garinii, Borrelia graingeri, Borrelia harveyi, Borrelia hermsii, Borrelia hispanica, Borrelia japonica, Borrelia kurtenbachii, Borrelia latyschewii, Borrelia lonestari, Borrelia lusitaniae, Borrelia mayonii, Borrelia mazzottii, Borrelia merionesi, Borrelia microti, Borrelia miyamotoi, Borrelia parkeri, Borrelia persica, Borrelia queenslandica, Borrelia recurrentis, Borrelia sinica, Borrelia spielmanii, Borrelia tanukii, Borrelia theileri, Borrelia tillae, Borrelia turcica, Borrelia turdi, Borrelia turicatae, Borrelia valaisiana, Borrelia venezuelensis, Borrelia vincentii, and Candidatus Borrelia texasensis. In one aspect, the one or more Borrelia species are Borrelia burgdorferi, Borrelia garinii, Borrelia mayonii, and/or Borrelia afzelii.


In some embodiments, the method further comprises detecting in the sample a Babesia species, an Ehrlichia species, a Bartonella species, Francisella tularensis, Yersinia pestis, Staphylococcus aureus, Anaplasma phagocytophilum, Enterovirus, Powassan and deer tick virus, Rickettsia species, and/or Influenza by subjecting DNA and/or RNA from the sample to a PCR amplification reaction using primer pairs containing sequences selected from the group consisting of SEQ ID NOS: 49-59, SEQ ID NOS: 78-96, SEQ ID NOS: 105-108, and SEQ ID NOS: 294-314.


In other aspects, the sample is whole blood, serum, plasma, buffy coat or connective tissue.


In some embodiments, the subject is an animal. In one embodiment, the animal is a human. In another embodiment, the template is RNA.


In some embodiments, the present invention is directed to a kit for detection of one or more Borrelia species causing Lyme Disease or TBRF, the kit comprising: primer pairs targeting at least one region of Borrelia 16S rRNA and at least one region of flaB, ospA, ospB, ospC, glpQ, 16S-23S intergenic spacer (IGS1), 5S-23S intergenic spacer (IGS2), bbk32, dbpA, dbpB, and/or p66.


In one embodiment, the primer pairs in the kit targeting at least one region of Borrelia 16S rRNA contain sequences selected from the group consisting of SEQ ID NOS: 1-10.


In certain aspects, the primer pairs in the kit targeting at least one region of flaB, ospA, ospB, ospC, glpQ, 16S-23S intergenic spacer (IGS), 5S-23S intergenic spacer (IGS2), bbk32, dbpA, dbpB, and/or p66 contain sequences selected from the group consisting of SEQ ID NOS: 11-48, SEQ ID NOS: 60-77, SEQ ID NOS: 97-100, and SEQ ID NOS: 219-293.


In other aspects, the kit further comprises primer pairs containing sequences selected from the group consisting of SEQ ID NOS: 49-59, SEQ ID NOS: 78-96, SEQ ID NOS: 105-108, and SEQ ID NOS: 294-314.for detecting a Babesia species, an Ehrlichia species, a Bartonella species, Francisella tularensis, Yersinia pestis, Staphylococcus aureus, Anaplasma phagocytophilum, Enterovirus, Powassan and deer tick virus, Rickettsia species, and/or Influenza.


In yet other aspects, the primer pairs in the kit comprise a universal tail sequence. In one aspect, the kit further comprises a nucleotide polymerase, buffer, diluent, and/or excipient.


In one aspect, the kit further comprises one or more primers comprising a sequence selected from SEQ ID NOS: 109 and 110 for amplifying human GAPDH as an internal control.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 depicts a workflow for the LymeSeq Lyme Disease Next-Generation Sequencing Diagnostic Assay.



FIG. 2 depicts a configuration of multiplex assays used with the LymeSeq Lyme Disease Next-Generation Sequencing Diagnostic Assay to rapidly and accurately diagnose Lyme Disease.



FIG. 3 depicts the Borrelia flaB gene tree with the Borrelia species in the Borrelia burdorferi sensu lato group clustering together and the Borrelia species in the tick-borne relapsing fever (TBRF) species group clustering together.



FIG. 4 depicts mapping of flaB sequence reads against 482 unique DNA sequences to identify Borrelia species that cause Lyme Disease and Borrelia species that do not cause Lyme Disease. For example, the sequence ATGGCCCTATCAT (SEQ ID NO: 476) is specific to Borrelia burdorferi while the sequence ATGGCTTTATAAT (SEQ ID NO: 477) is specific to Borrelia hersmii.



FIG. 5 depicts the Borrelia 16S rDNA tree with the Borrelia species in the Borrelia burdorferi sensu lato group clustering together and the Borrelia species in the tick-borne relapsing fever (TBRF) species group clustering together.



FIG. 6 depicts mapping of Borrelia 16S rDNA sequence reads against 185 unique DNA sequences to identify Borrelia species that cause Lyme Disease and Borrelia species that do not cause Lyme Disease. The arrows depict forward and reverse primers that produce amplicons covering the majority of the Borrelia 16S rDNA sequence.



FIG. 7 depicts colony forming units (CFU) of Borrelia burgdorferi in spiked blood samples plotted against the number of sequence reads for 16S rRNA, flaB-1, flaB-2, and ospB after analysis of either extracted RNA or extracted DNA from the samples. Trendlines are indicated with solid or dashed lines.





DETAILED DESCRIPTION

The present invention provides a method of detecting and characterizing one or more Borrelia species causing Lyme Disease or TBRF within a sample from a subject and addresses the challenges of co-infection that may confound test results, unspecific testing causing false positives on Lyme disease diagnostic tests, and the limited sensitivity available with other methods of detection.


The present invention overcomes these challenges by providing a method A method of detecting one or more Borrelia species causing Lyme Disease or tick-borne relapsing fever (TBRF) within a sample from a subject, the method comprising: a) subjecting DNA and/or RNA from the sample to a PCR amplification reaction using primer pairs targeting at least one region specific to the Borrelia genus, at least one region specific to Borrelia burgdorferi, and/or at least one non-Lyme Borrelia spp. region; and b) analyzing amplification products resulting from the PCR amplification reaction to detect the one or more Borrelia species.


In some embodiments, the primer pairs of the present invention target at least one region of an outer surface protein gene of Borrelia burgdorferi. The Borrelia burgdorferi outer surface proteins include ospA, ospB, ospD, ospC, bba64, ospF, bbk32, dbpA, dbpB, and vlsE. Borrelia burgdorferi outer surface proteins play role in persistence within ticks (ospA, ospB, ospD), mammalian host transmission (ospC, bba64), host cell adhesion (ospF, bbk32, dbpA, dbpB), and in evasion of the host immune system (vlsE). OspC triggers innate immune system via signaling through TLR1, TLR2 and TLR6 receptors. See Oosting, Marije et al. (2016) “Innate immunity networks during infection with Borrelia burgdorferi,” Critical Reviews in Microbiology 42 (2): 233-244.


In certain aspects, the primer pairs of the present invention target at least one region of an intergenic spacer (IGS) region. An IGS region is a region of non-coding DNA between genes and includes the spacer DNA between the many tandemly repeated copies of the ribosomal RNA genes. In one aspect, the IGS region is the region between the 16S and the 23S genes (i.e., 16S-23S intergenic spacer (IGS1)) and/or the region between the 5S and the 23S genes (i.e., 5S-23S intergenic spacer (IGS2)).


In other aspects, the primer pairs of the present invention target at least one region of a porin gene in Borrelia burgdorferi. In some embodiments, the porin gene is selected from the group consisting of p66, p13 and oms28. In one aspect, the porin gene is p66.


In yet other aspects, the primer pairs of the present invention target at least one region of a glycerophosphodiester phosphodiesterase gene (glpQ) from Borrelia spp.


In some embodiments, the primer pairs of the present invention target at least one region of ospA, ospC, CRASP (complement regulator-acquiring surface protein) including CRASP-1 (cspA), CRASP-2 (cspZ), CRASP-3 (erpP), CRASP-4 (erpC), CRASP-5 (erpA), Erp (OspEF-related protein) A, C, and P, bbk32, dbp (decorin-binding proteins) A and B, bgp (Borrelia glycosaminoglycan-binding protein), revA, revB, bb0347, erpX, p66, bbb07, ospC, vlsE, lmp1, and/or ospF family (ospF and G, erpK and L). See Coburn, J., et al. (2013) “Illuminating the roles of the Borrelia burgdorferi adhesins,” Trends in Microbiology, 21(8), 372-379.


As used herein, “amplification reaction” refers to a method of detecting target nucleic acid by in vitro amplification of DNA or RNA.


As used herein, “polymerase chain reaction (PCR)” refers to the amplification of a specific DNA sequence, termed target or template sequence, that is present in a mixture, by adding two or more short oligonucleotides, also called primers, that are specific for the terminal or outer limits of the template sequence. The template-primers mixture is subjected to repeated cycles of heating to separate (melt) the double-stranded DNA and cooling in the presence of nucleotides and DNA polymerase such that the template sequence is copied at each cycle.


The term “primer” refers to DNA oligonucleotides complementary to a region of DNA and serves as the initiation of amplification reaction from the 5′ to 3′ direction.


The term “primer pair” refers to the forward and reverse primers in an amplification reaction leading to amplification of a double-stranded DNA region of the target.


The term “target” refers to a nucleic acid region bound by a primer pair that is amplified through an amplification reaction. The PCR “product” or “amplicon” is the amplified nucleic acid resulting from PCR of a set of primer pairs.


The term “multiplex amplification reaction” herein refers to the detection of more than one template in a mixture by the addition of more than one set of oligonucleotide primers.


As described in greater detail herein, some embodiments of the invention may include amplicon-based sequencing of the one or more markers to make the aforementioned determinations. Some embodiments of the invention include systems and methods of preparing samples for one or more downstream processes that can be used for assessing one or more markers for any of the previously mentioned purposes. Some embodiments of the invention may comprise a universal indexing sequencing strategy for use in downstream sequencing platform processes. By way of example only, some embodiments of the invention comprise a universal indexing sequencing strategy that can be used to amplify multiple genomic regions (e.g., markers, as described below) from a DNA sample simultaneously in a single reaction for the sequencing of one or more amplicons. One or more embodiments of the invention can be used with any desired sequencing platform, such as the ILLUMINA® Next Generation Sequencing (e.g., MiSEQ) platform, Life Technologies' Ion Torrent System, or any other sequencing system now known or developed in the future.


Some embodiments may be configured to enable relatively simple, rapid (e.g., microorganism-culture independent), inexpensive, and efficient preparation of samples for use on, in, and/or with downstream sequencing platforms. For example, some embodiments may use a sequence coupled to one or more oligonucleotides/primers (as used herein, oligonucleotides and primers are used interchangeably). More specifically, one or more amplicons per sample can be generated using a hybrid oligonucleotide that is designed for amplification of a marker and incorporation of at least one universal tail sequence into the resulting amplicon. As a result, additional steps that may be conventionally required to prepare samples for sequencing can be limited or removed entirely. Further information regarding the universal tail, amplicon-based sequencing strategy can be found in PCT/US2014/064890, which is hereby incorporated by reference in its entirety for all purposes.


In some embodiments, the methodology may include performing downstream sequencing on one or more amplicons. For example, in order to minimize and/or eliminate the need for cultures of microorganisms or large inputs of nucleic acids, methodologies of the instant invention may include an initial PCR step to create amplicons that correspond to the one or more pre-selected markers. As such, some embodiments require only limited amounts of starting material are necessary and the starting material need not be of high quality (e.g., genomic DNA, crude DNA extracts, single stranded DNA, RNA, cDNA, etc.). In contrast, many conventional sample preparation systems may require relatively large amounts of starting material of relatively high quality, which can limit the use of some conventional systems.


Some embodiments of the invention can be used for and/or in complement with high-throughput amplicon sequencing of markers, which can be very useful for a variety of molecular genetic genotyping/predicted-phenotyping applications, including clinical sample analysis. For example, use of the systems and methods of the invention can be employed with sequencing platforms to provide rapid, high-yield sequence data, which can enable the sequencing of multiple markers/amplicons from many samples in a relatively short period of time. Specifically, in some embodiments, amplicons can be selected and PCR reactions can be designed to provide information that can be used to make clinically relevant determinations after sequencing of the amplicons.


In some preferred aspects, the methodology may include creating a series of oligonucleotides designed to provide multiplexed amplification of one or more markers to produce the desired amplicons. In particular, the one or more markers and amplicons thereof can be selected/amplified to provide users with clinically relevant information related to identification of one or more potentially infectious microorganisms and/or viruses and phenotypic and genotypic information about the microorganisms and/or viruses (e.g., Borrelia strain identity and 16S-23S intergenic spacer (IGS) sequence variance). After production of the amplicons (e.g., via PCR amplification), which may include the universal tail sequences, the method may include processing the resulting amplicons for downstream sequencing and thereafter sequencing the processed amplicons. After processing and analysis of the resulting sequencing data, one of skill in the art can make any necessary determinations regarding the identification of one or more microorganisms and/or viruses that may have been contained within the sample and predicted-phenotypic and/or genotypic information revealed.


Generally, some embodiments of the present invention can be used to detect, identify, assess, sequence, or otherwise evaluate a marker. A marker may be any molecular structure produced by a cell, expressed inside the cell, accessible on the cell surface or secreted by the cell. A marker may be any protein, carbohydrate, fatty acid, nucleic acid, catalytic site, or any combination of these such as an enzyme, glycoprotein, cell membrane, virus, a particular cell, or other uni- or multimolecular structure. A marker may be represented by a sequence of a nucleic acid or any other molecules derived from the nucleic acid. Examples of such nucleic acids include miRNA, tRNA, siRNA, mRNA, cDNA, genomic DNA sequences, single-stranded DNA, or complementary sequences thereof. Alternatively, a marker may be represented by a protein sequence. The concept of a marker is not limited to the exact nucleic acid sequence or protein sequence or products thereof; rather it encompasses all molecules that may be detected by a method of assessing the marker. Without being limited by the theory, the detection, identification, assessment, sequencing, or any other evaluation of the marker may encompass an assessment of a change in copy number (e.g., copy number of a gene or other forms of nucleic acid) or in the detection of one or more translocations. Moreover, in some embodiments, the marker may be relevant to a particular phenotype or genotype. By way of example only, in some embodiments, the marker may be related to phenotypes including antibiotic resistance, virulence, or any other phenotype.


Therefore, examples of molecules encompassed by a marker represented by a particular sequence further include alleles of the gene used as a marker. An allele includes any form of a particular nucleic acid that may be recognized as a form of the particular nucleic acid on account of its location, sequence, or any other characteristic that may identify it as being a form of the particular gene. Alleles include but need not be limited to forms of a gene that include point mutations, silent mutations, deletions, frameshift mutations, single nucleotide polymorphisms (SNPs), inversions, translocations, heterochromatic insertions, and differentially methylated sequences relative to a reference gene, whether alone or in combination. An allele of a gene may or may not produce a functional protein; may produce a protein with altered function, localization, stability, dimerization, or protein-protein interaction; may have overexpression, underexpression or no expression; may have altered temporal or spatial expression specificity; or may have altered copy number (e.g., greater or less numbers of copies of the allele). An allele may also be called a mutation or a mutant. An allele may be compared to another allele that may be termed a wild type form of an allele. In some cases, the wild type allele is more common than the mutant.


In some aspects, the markers may include one or more sets of amplifiable nucleic acids that can provide diagnostic information about the microorganisms and/or viruses. For example, the markers may include amplifiable nucleic acid sequences that can be used to assess the presence and/or absence of one or more microorganism and/or virus that may have the potential to cause a diseased state in the subject. In some embodiments, the markers may include amplifiable nucleic acid sequences that can be used to identify one or more of the following exemplary microorganisms and/or viruses: Borrelia spp. (including but not limited to Borrelia afzelii, Borrelia americana, Borrelia andersonii, Borrelia anserina, Borrelia baltazardii, Borrelia bavariensis, Borrelia bissettii, Borrelia brasiliensis, Borrelia burgdorferi, Borrelia californiensis, Borrelia carolinensis, Borrelia caucasica, Borrelia coriaceae, Borrelia crocidurae, Borrelia dugesii, Borrelia duttonii, Borrelia garinii, Borrelia graingeri, Borrelia harveyi, Borrelia hermsii, Borrelia hispanica, Borrelia japonica, Borrelia kurtenbachii, Borrelia latyschewii, Borrelia lonestari, Borrelia lusitaniae, Borrelia mayonii, Borrelia mazzottii, Borrelia merionesi, Borrelia microti, Borrelia miyamotoi, Borrelia parkeri, Borrelia persica, Borrelia queenslandica, Borrelia recurrentis, Borrelia sinica, Borrelia spielmanii, Borrelia tanukii, Borrelia theileri, Borrelia tillae, Borrelia turcica, Borrelia turdi, Borrelia turicatae, Borrelia valaisiana, Borrelia venezuelensis, Borrelia vincentii, and Candidatus Borrelia texasensis), Anaplasma phagocytophilum, Ehrlichia spp., Staphylococcus aureus, Yersinia pestis, Francisella tularensis, Bartonella spp., Babesia spp., Influenza virus, and Enterovirus.


In some embodiments, the methods may include the use of one or more than one marker per microorganism or virus. Moreover, in some embodiments, one or more of the microorganisms and/or viruses may not be considered pathogenic to certain subjects, but the methodology employed herein can still rely on detection of pathogenic and non-pathogenic microorganisms and/or viruses for differential diagnoses/diagnostics. In some embodiments, the oligonucleotides (with or without the universal tail sequences detailed herein) listed in Table 1, Table 2, and Table 3 can be used with embodiments of the invention to amplify one or more markers from the microorganisms and/or viruses to provide diagnostic/identification information to the user.


Moreover, in some embodiments, one or more the markers associated with the plurality of microorganisms and/or viruses can be amplified in a multiplex manner. For example, in some aspects, nucleic acids can be obtained from the sample and the oligonucleotides used to amplify one or more of the markers used to identify/diagnose can be added to a single mixture to produce a plurality of amplicons in a single reaction mixture. In other aspects, the oligonucleotides can be added to multiple mixtures to provide for the creation of multiple amplicons in multiple mixtures.


Moreover, in some embodiments, one or more the markers can be amplified in a multiplex manner. For example, in some aspects, nucleic acids can be obtained from the sample and the oligonucleotides used to amplify one or more of the markers used to identify the strain of the microorganism or virus can be added to a single mixture to produce a plurality of amplicons in a single reaction mixture. In other aspects, the oligonucleotides can be added to multiple mixtures to provide for the creation of multiple amplicons in multiple mixtures. In some aspects, amplification of the markers used to identify microorganisms and/or viruses/diagnose an infection can also occur in a multiplex manner such that some or all of the amplicons are generated in a single reaction for a particular sample. In other aspects, amplification of the markers used to identify microorganisms and/or viruses/diagnose an infection can occur in multiple reaction vessels. Overall, as described in greater detail below, regardless of the multiplex nature of some embodiments of the invention, after amplification of the markers, the method may include processing and sequencing the resulting amplicons to provide information related to the identification, characterization, and strain identity of one or more microorganisms and/or viruses that may be present within the sample.


Some embodiments of the invention may comprise the use of one or more methods of amplifying a nucleic acid-based starting material (i.e., a template, including genomic DNA, crude DNA extract, single-stranded DNA, double-stranded DNA, cDNA, RNA, or any other single-stranded or double-stranded nucleic acids). Nucleic acids may be selectively and specifically amplified from a template nucleic acid contained in a sample. In some nucleic acid amplification methods, the copies are generated exponentially. Examples of nucleic acid amplification methods known in the art include: polymerase chain reaction (PCR), ligase chain reaction (LCR), self-sustained sequence replication (3SR), nucleic acid sequence based amplification (NASBA), strand displacement amplification (SDA), amplification with Qβ replicase, whole genome amplification with enzymes such as φ29, whole genome PCR, in vitro transcription with T7 RNA polymerase or any other RNA polymerase, or any other method by which copies of a desired sequence are generated.


In addition to genomic DNA, any polynucleotide sequence can be amplified with an appropriate set of primer molecules. In particular, the amplified segments created by the PCR process itself are, themselves, efficient templates for subsequent PCR amplifications.


PCR generally involves the mixing of a nucleic acid sample, two or more primers or oligonucleotides (primers and oligonucleotides are used interchangeably herein) that are designed to recognize the template DNA, a DNA polymerase, which may be a thermostable DNA polymerase such as Taq or Pfu, and deoxyribose nucleoside triphosphates (dNTP's). In some embodiments, the DNA polymerase used can comprise a high fidelity Taq polymerase such that the error rate of incorrect incorporation of dNTPs is less than one per 1,000 base pairs. Reverse transcription PCR, quantitative reverse transcription PCR, and quantitative real time reverse transcription PCR are other specific examples of PCR. In general, the reaction mixture is subjected to temperature cycles comprising a denaturation stage (typically 80-100° C.), an annealing stage with a temperature that is selected based on the melting temperature (Tm) of the primers and the degeneracy of the primers, and an extension stage (for example 40-75° C.). In real-time PCR analysis, additional reagents, methods, optical detection systems, and devices known in the art are used that allow a measurement of the magnitude of fluorescence in proportion to concentration of amplified template. In such analyses, incorporation of fluorescent dye into the amplified strands may be detected or measured.


Either primers or primers along with probes allow a quantification of the amount of specific template DNA present in the initial sample. In addition, RNA may be detected by PCR analysis by first creating a DNA template from RNA through a reverse transcriptase enzyme (i.e., the creation of cDNA). The marker expression may be detected by quantitative PCR analysis facilitating genotyping analysis of the samples.


“Amplification” is a special case of nucleic acid replication involving template specificity. Amplification may be a template-specific replication or a non-template-specific replication (i.e., replication may be specific template-dependent or not). Template specificity is here distinguished from fidelity of replication (synthesis of the proper polynucleotide sequence) and nucleotide (ribo- or deoxyribo-) specificity. Template specificity is frequently described in terms of “target” specificity. Target sequences are “targets” in the sense that they are sought to be sorted out from other nucleic acid. Amplification techniques have been designed primarily for this sorting out. The amplification process may result in the production of one or more amplicons.


The term “template” refers to nucleic acid originating from a sample that is analyzed for the presence of one or more markers. In contrast, “background template” or “control” is used in reference to nucleic acid other than sample template that may or may not be present in a sample. Background template is most often inadvertent. It may be the result of carryover, or it may be due to the presence of nucleic acid contaminants sought to be purified out of the sample. For example, nucleic acids from organisms other than those to be detected may be present as background in a test sample.


In addition to primers and probes, template specificity is also achieved in some amplification techniques by the choice of enzyme. Amplification enzymes are enzymes that, under the conditions in which they are used, will process only specific sequences of nucleic acid in a heterogeneous mixture of nucleic acid. Other nucleic acid sequences will not be replicated by this amplification enzyme. Similarly, in the case of T7 RNA polymerase, this amplification enzyme has a stringent specificity for its own promoters (Chamberlin et al. (1970) Nature (228):227). In the case of T4 DNA ligase, the enzyme will not ligate the two oligonucleotides or polynucleotides, where there is a mismatch between the oligonucleotide or polynucleotide substrate and the template at the ligation junction (Wu and Wallace (1989) Genomics (4):560). Finally, Taq and Pfu polymerases, by virtue of their ability to function at high temperature, are found to display high specificity for the sequences bounded and thus defined by the primers; the high temperature results in thermodynamic conditions that favor primer hybridization with the target sequences and not hybridization with non-target sequences (H. A. Erlich (ed.) (1989) PCR Technology, Stockton Press).


The term “amplifiable nucleic acid” refers to nucleic acids that may be amplified by any amplification method. It is contemplated that “amplifiable nucleic acid” will usually comprise “sample template.” The terms “PCR product,” “PCR fragment,” “amplification product,” and “amplicon” refer to the resultant mixture of compounds after two or more cycles of the PCR steps of denaturation, annealing and extension. These terms encompass the case where there has been amplification of one or more segments of one or more target sequences.


In some forms of PCR assays, quantification of a target in an unknown sample is often required. Such quantification may be determined in reference to the quantity of a control sample. The control sample starting material/template may be co-amplified in the same tube in a multiplex assay or may be amplified in a separate tube. Generally, the control sample contains template at a known concentration. The control sample template may be a plasmid construct comprising only one copy of the amplification region to be used as quantification reference. To calculate the quantity of a target in an unknown sample, various mathematical models are established. Calculations are based on the comparison of the distinct cycle determined by various methods, e.g., crossing points (CP) and cycle threshold values (Ct) at a constant level of fluorescence; or CP acquisition according to established mathematic algorithm.


Some embodiments of the invention may comprise a multiplex assay. As used herein, the term “multiplex” refers to the production of more than one amplicon, PCR product, PCR fragment, amplification product, etc. in a single reaction vessel. In other words, multiplex is to be construed as the amplification of more than one marker-specific sequences within a PCR reaction or assay within the same PCR assay mixture (e.g., more than one amplicon is produced within a single vessel that contains all of the reagents necessary to perform a PCR reaction). In some embodiments, a step prior to performing the PCR (or RT-PCR, quantitative RT-PCR, etc.) reaction can occur such that sets of primers and/or primers and probes are designed, produced, and optimized within a given set of reaction conditions to ensure proper amplicon production during the performance of the PCR.


The algorithm for Ct values in real time-PCR calculates the cycle at which each PCR amplification reaches a significant threshold. The calculated Ct value is proportional to the number of marker copies present in the sample, and the Ct value is a precise quantitative measurement of the copies of the marker found in any sample. In other words, Ct values represent the presence of respective marker that the primer sets are designed to recognize. If the marker is missing in a sample, there should be no amplification in the Real Time-PCR reaction.


Alternatively, the Cp value may be utilized. A Cp value represents the cycle at which the increase of fluorescence is highest and where the logarithmic phase of a PCR begins. The LIGHTCYCLER® 480 Software calculates the second derivatives of entire amplification curves and determines where this value is at its maximum. By using the second-derivative algorithm, data obtained are more reliable and reproducible, even if fluorescence is relatively low.


The various and non-limiting embodiments of the PCR-based method detecting marker expression level as described herein may comprise one or more probes and/or primers. Generally, the probe or primer contains a sequence complementary to a sequence specific to a region of the nucleic acid of the marker gene. A sequence having less than 60% 70%, 80%, 90%, 95%, 99% or 100% identity to the identified gene sequence may also be used for probe or primer design if it is capable of binding to its complementary sequence of the desired target sequence in marker nucleic acid.


Some embodiments of the invention may include a method of comparing a marker in a sample relative to one or more control samples. A control may be any sample with a previously determined level of expression. A control may comprise material within the sample or material from sources other than the sample. Alternatively, the expression of a marker in a sample may be compared to a control that has a level of expression predetermined to signal or not signal a cellular or physiological characteristic. This level of expression may be derived from a single source of material including the sample itself or from a set of sources.


The sample in this method is preferably a biological sample from a subject. The term “sample” or “biological sample” is used in its broadest sense. Depending upon the embodiment of the invention, for example, a sample may comprise a bodily fluid including whole blood, serum, plasma, urine, saliva, cerebral spinal fluid, semen, vaginal fluid, pulmonary fluid, tears, perspiration, mucus and the like; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print, or any other material isolated in whole or in part from a living subject or organism. Biological samples may also include sections of tissues such as biopsy and autopsy samples, and frozen sections taken for histologic purposes such as blood, plasma, serum, sputum, stool, tears, mucus, hair, skin, and the like. Biological samples also include explants and primary and/or transformed cell cultures derived from patient tissues.


In some embodiments, sample or biological sample may include a bodily tissue, fluid, or any other specimen that may be obtained from a living organism that may comprise additional living organisms. By way of example only, in some embodiments, sample or biological sample may include a specimen from a first organism (e.g., a human) that may further comprise an additional organism (e.g., bacteria, including pathogenic or non-pathogenic/commensal bacteria, viruses, parasites, fungi, including pathogenic or non-pathogenic fungi, etc.). In some embodiments of the invention, the additional organism may be separately cultured after isolation of the sample to provide additional starting materials for downstream analyses. In some embodiments, the sample or biological sample may comprise a direct portion of the additional, non-human organism and the host organism (e.g., a biopsy or sputum sample that contains human cells and bacteria).


With respect to use of the sample or biological sample, embodiments of the claimed methodology provide improvements compared to conventional methodologies. Specifically, conventional methodologies of identifying and characterizing microorganisms include the need for morphological identification and culture growth. As such, conventional methodologies may take an extended period of time to identify the microorganism and may then require further time to identify whether the microorganism possesses and certain markers. Some embodiments of the invention can provide a user with information about any microorganisms and/or viruses present in a sample without the need for additional culturing because of the reliance of nucleic acid amplification and sequencing. In other words, direct extraction of nucleic acids coupled with amplification of the desired markers and downstream sequencing can reduce significantly the time required to obtain diagnostic and strain identifying information.


The invention may further comprise the step of sequencing the amplicon. Methods of sequencing include but need not be limited to any form of DNA sequencing including Sanger, next-generation sequencing, pyrosequencing, SOLiD sequencing, massively parallel sequencing, pooled, and barcoded DNA sequencing or any other sequencing method now known or yet to be disclosed.


In Sanger Sequencing, a single-stranded DNA template, a primer, a DNA polymerase, nucleotides and a label such as a radioactive label conjugated with the nucleotide base or a fluorescent label conjugated to the primer, and one chain terminator base comprising a dideoxynucleotide (ddATP, ddGTP, ddCTP, or ddTTP, are added to each of four reaction (one reaction for each of the chain terminator bases). The sequence may be determined by electrophoresis of the resulting strands. In dye terminator sequencing, each of the chain termination bases is labeled with a fluorescent label of a different wavelength that allows the sequencing to be performed in a single reaction.


In pyrosequencing, the addition of a base to a single-stranded template to be sequenced by a polymerase results in the release of a pyrophosphate upon nucleotide incorporation. An ATP sulfuryrlase enzyme converts pyrophosphate into ATP that in turn catalyzes the conversion of luciferin to oxyluciferin which results in the generation of visible light that is then detected by a camera or other sensor capable of capturing visible light.


In SOLiD sequencing, the molecule to be sequenced is fragmented and used to prepare a population of clonal magnetic beads (in which each bead is conjugated to a plurality of copies of a single fragment) with an adaptor sequence and alternatively a barcode sequence. The beads are bound to a glass surface. Sequencing is then performed through 2-base encoding.


In massively parallel sequencing, randomly fragmented targeted nucleic acids and/or amplicons are attached to a surface. The fragments/amplicons are extended and bridge amplified to create a flow cell with clusters, each with a plurality of copies of a single fragment sequence. The templates are sequenced by synthesizing the fragments in parallel. Bases are indicated by the release of a fluorescent dye correlating to the addition of the particular base to the fragment.


Nucleic acid sequences may be identified by the IUAPC letter code which is as follows: A—Adenine base; C—Cytosine base; G—guanine base; T or U—thymine or uracil base; I—inosine base. M—A or C; R—A or G; W—A or T; S—C or G; Y—C or T; K—G or T; V—A or C or G; H—A or C or T; D—A or G or T; B—C or G or T; N or X—A or C or G or T. Note that T or U may be used interchangeably depending on whether the nucleic acid is DNA or RNA. A sequence having less than 60%, 70%, 80%, 90%, 95%, 99% or 100% identity to the identifying sequence may still be encompassed by the invention if it is able of binding to its complimentary sequence and/or facilitating nucleic acid amplification of a desired target sequence. In some embodiments, as previously mentioned, the method may include the use of massively parallel sequencing, as detailed in U.S. Pat. Nos. 8,431,348 and 7,754,429, which are hereby incorporated by reference in their entirety.


Some embodiments of the invention comprise multiple steps and/or processes that are carried out to execute the universal tail indexing strategy to prepare amplicons corresponding to desired markers for sequencing. In some embodiments, one or more makers for a given sample or template can be selected, as described above. Some embodiments of the invention can be used in conjunction with an analysis of one or more markers (e.g., genes/alleles) associated with a particular phenotype (e.g., virulence).


After selection of the markers, marker-specific primers/oligonucleotides can be designed for the amplification of the markers to produce the desired amplicons, as detailed above. As is known in the art, a forward and a reverse marker-specific primer can be designed to amplify the marker from a nucleic acid sample. In some embodiments, the forward and reverse primers can be designed to produce an amplicon (e.g., some or all of the sequence of the marker) of a desired length. For example, the length of the amplicon may comprise approximately 50 base pairs (bp), 100 bp, 150 bp, 200 bp, 250 bp, 300 bp, 350 bp, 400 bp, 450 bp, 500 bp, 1,000 bp, or any size amplicon greater in size or therebetween.


As previously mentioned, some embodiments of the invention may include a multiplex PCR reaction. For example, marker-specific primers can be designed for multiple markers or multiple regions of the same marker such that multiple amplicons of between about 50 bp and 1,000 bp are being produced within a single PCR reaction vessel. In other words, the forward and reverse primers can be designed to function within a given set of temperature parameters such that more than one amplicon can be successfully amplified from a given template within a single PCR reaction mixture. As such, multiple amplicons can be prepared using the universal tail indexing strategy for sequencing preparation.


In some embodiments, the forward and reverse primers that have been designed for each of the markers can be modified to include a universal tail. For example, the universal tail sequences can be relatively or completely unique sequences of nucleotides that are coupled to the 5′ ends of some or all of the forward and reverse marker-specific primers. In some aspects, the universal tail sequences can be selected such that there is little to no overlap in sequence between portions of the markers that are being amplified and the universal tail sequences. Moreover, the universal tail sequences can comprise a length between ten and twenty nucleotides in length. In some embodiments, the universal tail sequences can be any other length, as desired by the user to meet the needs and requirements of the reaction. As such, the universal tail sequences can exhibit a relatively negligible impact on binding of the forward and reverse marker-specific primers to the template sequence to enable amplification. Moreover, as a result of being included on the 5′ end of the forward and reverse marker-specific primers, the universal tail sequences will form a portion of the resulting amplicons. In addition, in some aspects of the invention, the sequences selected for the universal tail sequences can be at least partially correlated with the chemical composition of the template nucleic acids. For example, in some aspects, the sequences selected for the universal tail sequences can be at least partially correlated with the G-C content of the organism from which the template is isolated.


In some aspects, some or all of the universal tail sequences can be at least partially unique. In some embodiments, each of the 5′ ends of all of the forward marker-specific primers within a given PCR assay mixture can comprise the same or a similar universal tail sequence (e.g., a first universal tail sequence or UT1). Similarly, each of the 5′ ends of all of the reverse marker-specific primers within the same PCR assay mixture can comprise a second universal tail sequence (UT2) that differs from the first universal tail sequence. As such, each respective sample from which a template sequence is used in the multiplex PCR assay will have two unique universal tail sequences. Accordingly, each forward and reverse marker-specific primer within a multiplex PCR mixture will include a unique universal tail sequence. For example, if the PCR includes 35 different samples, 35 universal tail sequences can be employed for the forward primers in each of the 35 unique reactions (i.e., not including technical replicates) and 35 universal tail sequences can be employed for the reverse primers in each of the 35 unique reactions (i.e., not including technical replicates). Overall, the forward and reverse marker-specific primers that each comprise the universal tail sequences can comprise a generally short length (e.g., 25-50 bp), which can facilitate simultaneous amplification of multiple targets in a single reaction.


In addition, some embodiments of the invention may comprise performing quantitative PCR to optimize the multiplex PCR assay. For example, after design of the forward and reverse marker-specific primers that each include a universal tail sequence, the contemplated multiplex PCR assays can be performed using quantitative PCR (e.g., using DNA as a template) to assess relative quantities of the amplicons produced. Accordingly, the sequence coverage of each amplicon is considered to be equal if the quantities of the amplicons produced by the multiplex quantitative PCR appear to be equal. If the quantities of the amplicons produced by the multiplex quantitative PCR do not appear to be equal, the forward and/or reverse marker-specific primers can be altered and re-optimized until adequate quantities of amplicons are produced.


After design and adequate optimization of the multiplex PCR assay comprising multiple forward and reverse marker-specific primers that each includes universal tail sequences, the multiplex PCR can be performed to obtain the amplicons associated with the above-described markers. In some embodiments, template that has been previously isolated from a sample can be used for the amplification of the amplicons. In some aspects, multiple PCR reaction replicates can be performed for each sample template and one or more control templates.


In some embodiments, after successful production of the amplicons during the multiplex PCR assay, the resulting amplicons can be further processed to provide sequencing-ready amplicons. For example, some embodiments of the invention may comprise an indexing extension step. In some aspects, the indexing extension step may comprise extending the optimized multiplex amplicons using a set of indexing and common primers that recognize the respective universal tail sequences used for the particular group of amplicons in a minimal cycle PCR assay (e.g., 5-10 total cycles). In particular, each multiplex set of amplicons to be sequenced can be extended with a different set of index oligonucleotides and common oligonucleotides that recognize UT1 and UT2, respectively. In some aspects, the index sequence of the index oligonucleotides can be custom designed to allow for the selection of an index sequence from potentially thousands of different index sequences.


After this step, the resulting products include a set of amplicons for each sample/template that comprise the same index and any necessary sequences that may be required for a particular sequencing platform (e.g., platform sequences associated with the ILLUMINA® Next Generation sequencing platform). Thereafter, the resulting extension-reaction products can be quantified, pooled, and sequenced using a desired platform. In some aspects, the inclusion of the universal tail sequences on the index and common primers can coincide with the use of genomic and index read primers in the mixture of sequencing primer reagents. For example, some embodiments of the invention are capable of pooling multiple amplicons with multiple indices in a single sequencing run to provide 40,000×-95,000× coverage across the amplicons. In other embodiments, the systems and methods associated with the invention can be configured to provide any level of sequencing coverage that is desirable to the user (e.g., higher or lower that the coverage levels discussed above). In some embodiments, after sequencing and generation of the sequence data, the resulting data can be demultiplexed and the sequence files can be aligned to the appropriate references sequences for subsequent sequence analyses.


Embodiments of the invention offer additional advantages relative to conventional systems. For example, some embodiments of the invention comprise the use of PCR before sequencing such that only limited amounts of starting material are necessary and the starting material need not be of high quality (e.g., genomic DNA, crude DNA extracts, single stranded DNA, RNA, cDNA, etc.). In contrast, many conventional sample preparation systems may require relatively large amounts of starting material of relatively high quality, which can limit the use of these systems. Moreover, the inclusion of non-desirable template materials can also interfere in one or more downstream processes in conventional systems and methods. For example, if an investigation is being conducted that focuses on one or more organisms that may be associated with another organism (e.g., bacteria associated with a human); the sampling of the target organism may result in template contamination from the host organism.


In particular, in some aspects, obtaining samples of pathogenic or commensal bacteria from, on, or within a human may also result in the collection of human tissue. As such, when isolating the template, human nucleic acids may contaminate the bacterial template. Some embodiments of the invention are configured such that the contaminating template (e.g., from a human) would not interfere with downstream processes, including sequencing. For example, some embodiments of the invention operate such that only a limited amount of starting template (e.g., 500 femtograms or greater) can be used. Moreover, some embodiments are also configured such that the starting material (e.g., template contaminated with foreign nucleic acids) can still produce the required amplicons for sequencing in the presence of more than a 1,000-fold excess of contaminating template with no discernible inhibition of the multiplex PCR.


In certain aspects, the present invention provides an assay that works with as little as about 1 pg, about 900 fg, about 800 fg, about 700 fg, about 600 fg, about 500 fg, about 400 fg, about 300 fg, about 200 fg, or about 100 fg of genomic DNA.


The following examples are given for purely illustrative and non-limiting purposes of the present invention.


EXAMPLES
Example 1. Multiplex Assays for LymeSeq Lyme Disease Next-Generation Sequencing Diagnostic Assay

In one aspect, the LymeSeq Lyme Disease Next-Generation Sequencing Diagnostic Assay involves the steps of DNA or RNA extraction, amplification and library preparation, next-generation sequencing (NGS sequencing), reference mapping, and clinical interpretation as shown in FIG. 1. Amplification and library preparation can be efficiently carried out with multiplex assays of various configurations.


In one aspect, the LymeSeq Lyme Disease Next-Generation Sequencing Diagnostic Assay comprises the configuration of multiplex assays with the following primers identified in Table 1 without universal tails and in Table 2 and Table 3 with universal tails.

    • Multiplex 1 assays: 16S-1_UT, 16S-2_UT, 16S-3_UT, 16S-4_UT. 16S-5_UT, Ana-msp2_UT1, bbk32_UT, dbpA_UT, dbpB_UT, Ehrl-16S_UT, Ehrl-sodB_UT, EV-D68_UT, flaB_UT1, flaB_UT2, Ft-G_UT, glpQ_UT1, IGS-5S-23S-TK_UT, IGS1-Bunikis_UT1, IGS2-Derdakova_UT, ospA-Rudenko_UT, ospB_UT1, ospB_UT2, ospC-Bunikis_UT1, ospD_UT1, p66_UT1, parA_UT1, Yp3a_UT, Yppla_UT, H3N2_UT, Bart-ssrA_UT1, Babe-18S_UT1, IPC-gapDH_UT1, and Sa_M4_UT1.


      When this configuration of the multiplex assays is used, an amplification reaction mixture is prepared. After the amplification reactions are complete next-generation sequencing is carried out to determine the sequences of the amplicons. The sequences may be analyzed with reference mapping and further analyzed to arrive at a clinical interpretation.


As shown in FIG. 2, the configuration of Multiplex 1 assays includes:

    • 1) Borrelia genus-wide assays targeting the Borrelia 16S rRNA, the 16S-23S intergenic spacer (IGS), and the flaB gene (flagella subunit B);
    • 2) Borrelia burgdorferi sensu lato-specific assays targeting the adhesin genes (e.g., bbk32, dbpA, and dbpB) outer surface protein genes (e.g. ospA, ospB, and ospC), and p66 porin genes;
    • 3) a non-Lyme Borrelia spp. assay targeting the glpQ gene;
    • 4) assays specific to other tick-borne pathogens including Erlichia spp., Anaplasma phagocytophilum, Babesia spp., Bartonella spp., Powassan and deer tick viruses, and Rickettsia spp.;
    • 5) Lyme-like differential diagnostic assays specific to Staphylococcus aureus, Yersinia pestis, Influenza virus, Enterovirus, and Francisella tularensis; and
    • 6) an internal control assay targeting the human GAPDH gene.


The amplification and sequencing of regions of the flaB gene allows for the differentiation of the tick-borne relapsing fever (TBRF) species group from the Borrelia burgdorferi sensu lato group as shown in FIG. 3. The primers of the multiplex assays are designed to detect all Borrelia species and are located in conserved regions. Comparison of the sequenced amplicons from a sample are compared to an alignment of 482 known unique flaB gene DNA sequences to determine the presence or absence of particular Borrelia species that contribute to disease states such as Lyme disease and relapsing fever (see FIG. 4). Similarly, sequencing of amplicons from five assays covering the majority of the gene sequence of the Borrelia 16S rDNA and comparison of the sequences detected in a sample to an alignment of 185 known unique DNA sequences facilitates detection of Borrelia species in the TBRF species group and in the Borrelia burgdorferi sensu lato (Lyme) group (see FIG. 5 and FIG. 6).


Example 2. Sensitivity Results with LymeSeq Lyme Disease Next-Generation Sequencing Diagnostic Assay

Eight strains of Borrelia burgdorferi sensu lato were serially diluted and the DNA extracted from each diluted strain. After amplification using primers from Table 3 and next-generation sequencing the results showed that each strain was properly identified and the number of sequence reads mapping to the 16S rRNA reference correlated with the dilution factor of each sample.


Example 3. Detection of Borrelia Species in DNA Extracted from Ixodes pacificus

Seventy-four Western black-legged tick (Ixodes pacificus) samples were collected form the San Francisco Bay area and the DNA of each sample was extracted and analyzed as described in Example 1 with the following primers from Table 2:

    • 16S_UT, IGS2-5S-23S-TK_UT, IGS1-Bunikis_UT1, bbk32_UT, dbpA_UT, dbpB_UT, flaB_UT1, flaB_UT2, glpQ_UT1, ospA-Rudenko_UT, ospB_UT2, ospC-Bunikis_UT1, ospD_UT1, p66_UT1, parA_UT1, IPC-gapDH_UT1, Ana-msp2_UT1, Ehrl-16S_UT, Ehrl-sodB_UT, EV-D68_UT, Ft-G_UT, Yp3a_UT, Yppla_UT, H3N2_UT, Bart-ssrA_UT1, Babe-18S_UT1, Sa_M4_UT1


      After the amplicons were sequenced and analyzed with the LymeSeq Lyme Disease Next-Generation Sequencing Diagnostic Assay twenty-seven samples were found to contain genomic DNA from Borrelia burgdorferi sensu lato, eight samples contains genomic DNA from B. miyamotoi, one sample contained genomic DNA from Bartonella spp., and one sample contained genomic DNA from Anaplasma phagocytophilum.


Example 4. Investigation of Tick-Borne Relapsing Fever Outbreak with LymeSeq Lyme Disease Next-Generation Sequencing Diagnostic Assay


Borrelia hermsii is one of the species causing tick-borne relapsing fever (TBRF) in infected patients. An outbreak of TBRF was investigated in Northern Arizona (see Jones, J M et al., “Tick-Borne Relapsing Fever Outbreak among a High School Football Team at an Outdoor Education Camping trip, Arizona, 2014,” Am. J. Trop. Med. Hyg. 95(3), 2016, pp. 546-550). Blood was collected from several patients who were febrile after recent tick exposure. Eight blood samples were analyzed with the LymeSeq Lyme Disease Next-Generation Sequencing Diagnostic Assay as described in Example 1, and the assay indicated that seven of the eight were positive for Borrelia hermsii. TBRF was confirmed in several of these patients by spirochetemia detection on blood smear and/or by culturing blood samples from the patients and isolating Borrelia hermsii.


Example 5. Analysis of DNA Versus RNA with LymeSeq Lyme Disease Next-Generation Sequencing Diagnostic Assay in Spiked Blood Samples and TBRF Outbreak Blood Samples

Blood samples were spiked with Borrelia burgdorferi and subsequently analyzed with the LymeSeq Lyme Disease Next-Generation Sequencing Diagnostic Assay. Amplicon sequencing allows for analysis of extracted RNA as well as DNA. Both DNA and RNA were extracted from the spiked blood samples and analyzed as described in Example 1. The colony forming units (CFU) of Borrelia burgdorferi were counted in each spiked blood sample and plotted against the number of sequence reads for 16S rRNA, flaB-1, flaB-2, and ospB from each sample of extracted RNA or DNA (see FIG. 7). The results showed evidence of 16S rRNA in blood at a relatively high level even when very few Borrelia burgdorferi CFUs were present suggesting that extraction and analysis of RNA samples increased the sensitivity of the LymeSeq Lyme Disease Next-Generation Sequencing Diagnostic Assay as compared to extraction and analysis of DNA samples.


In another experiment, eight blood samples known to contain Borrelia hermsii were analyzed with the LymeSeq Lyme Disease Next-Generation Sequencing Diagnostic Assay. DNA and RNA from each sample were analyzed. The assay confirmed the presence of Borrelia hermsii in all eight samples. In addition, the sequence reads from the extracted RNA samples were generally greater than those from the corresponding extracted DNA samples. For instance, in one example the extracted DNA produced only 200 sequence reads while the corresponding extracted RNA produced 200,000 sequence reads. These results confirmed the enhanced sensitivity of the assay when used to analyze RNA samples.


Unless defined otherwise, all technical and scientific terms herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All publications, patents, and patent publications cited are incorporated by reference herein in their entirety for all purposes.


It is understood that the disclosed invention is not limited to the particular methodology, protocols and materials described as these can vary. It is also understood that the terminology used herein is for the purposes of describing particular embodiments only and is not intended to limit the scope of the present invention which will be limited only by the appended claims.


Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.









TABLE 1







Universal tail targets and assays for LymeSeq Lyme Disease Next-Generation


Sequencing Diagnostic Assay. The primers listed do not include the universal tails (UT).
















Target




SEQ


Target
Target
Gene/



Sequence without
ID


Purpose
Taxon
Region
UT Assay Type
Assay
Primer
UT
NO:

















Species

Borrelia

16S-
Sequence-based
16S-1_UT
16S-1_UT_F
CGGGTGAGTAAC
1


ID
spp.
set of



GCGTGGAT





5 assays to









cover whole









gene













Also good RNA

16S-1_UT_R
CCTCTCAGGCCG
2





target


GTTACTTATC










16S-2_UT
16S-2_UT_F
CGGTCACACTGG
3








AACTGAGA











16S-2_UT_R
GCTGCTGGCACG
4








TAATTAGC










16S-3_UT
16S-3_UT_F
GCGAGCGTTGTT
5








CGGGAT











16S-3_UT_R
ACTCAGCGTCAG
6








TCTTGACC










16S-4_UT
16S-4_UT_F
CGCTGTAAACGA
7








TGCACACTTG











I6S-4_UT_R
ACAACCATGCAG
8








CACCTGTA










16S-5_UT
16S-5_UT_F
GCAACGAGCGCA
9








ACCCTT











16S-5_UT_R
TACAAGGCCCGA
10








GAACGTATTCAC






Species

Borrelia

IGS2 5S-
Sequence-based
IGS2-5S-23S-
IGS-5S-23S-
GAGTTCGCGGGA
11


ID
spp.
23S

TK_UT
TK_UT_F
GAGTAGGTTATT









GCC








rrfA-rrlB
Also good RNA

IGS-5S-23S-
TCAGGGTACTTA
12





target

TK_UT_R
GATGKTTCACTT









CC










IGS2-5S-23S-
IGS-5S-23S-
CTGCGAGTTCGC
13






Postic_UT
Postic_UT_F
GGGAGA











IGS-5S-23S-
TCCTAGGCATTC
14







Postic_UT_R
ACCATA










IGS2-
IGS2-
CGACCTTCTTCGC
15






Derdakova_UT
Derdakova_UT
CTTAAAGC








F












IGS2-
AGCTCTTATTCGC
16







Derdakova_UT
TGATGGTA








R







Species

Borrelia

IGS1
Sequence-based
IGS1-
IGS1-
GTATGTTTAGTG
17


ID
spp.


Bunikis_UT1
Bunikis_UT1_F
AGGGGGGTG








rrs-rrlA
Also good RNA

IGS1-
GGATCATAGCTC
18





target

Bunikis_UT1
AGGTGGTTAG








R











IGS1-
IGS1-
AGGGGGGTGAAG
19






Bunikis_UT2
Bunikis_UT2_F
TCGTAACAAG











IGS1-
GTCTGATAAACC
20







Bunikis_UT2
TGAGGTCGGA








R







Species

Borrelia

IGS rrs-rrlA

rrs-rrlA_UT1
rrs-
GGGTTCGAGTCC
219


ID
spp.
16S-23S


rrlA_UT1_F1
CTYAACCT





IGS















rrs-
TTGGTTTAGAGC
220







rrlA_UT1_F2
ATCGGCTTTGC











rrs-
CCTTGCACTTTAG
221







rrlA_UT1_R1
CGAAACAAC











rrs-
CCTTGTGCTTTAG
222







rrlA_UT1_R2
TGAAACAAC











rrs-
ACTTGCCATACG
223







rrlA_UT1_R3
TAAACAACCGT











rrs-
CTCATGACTTGTC
224







rrlA_UT1_R4
ACACGTAAACAA









C











rrs-
GTTCAACTCCTCC
225







rrlA_UT1_R5
TGGTCCCAA











rrs-
ATCCTATAGATG
226







rrlA_UT1_R6
CAATCTCTTGWC









C











rrs-
TTTGCATGTAATC
227







rrlA_UTI_R7
AAGTCTTGGAAT









TC











rrs-
TACTTTCACCTCT
228







rrlA_UTI_R8
AGACATTCTTGT











rrs-
TAGGTTGATTCA
229







rrlA_UTI_R9
TGATCAGGTCCT









T











rrs-
CGATTCGGTCAC
230







rrlA_UTI_R1O
GGCTCTTAC











rrs-
CCTTATGATTTAG
231







rrlA_UTI_R11
TAACACAACGTA









AGT











rrs-
AAGCTAGTAATG
232







rrlA_UTI_R12
AATGTGGGATGT









T






Species

Borrelia

flaB
Sequence-based
flaB_UT1
flaB_UTI_F
GCWTCTGATGAT
21


ID
spp.




GCTGCTGGIA











flaB_UTI_R1
GCATTCCAAGYT
22








CTTCAGCTGT











flaB_UTI_R2
GCATTCCAAGCT
23








CTTCAGCWGT










flaB_UT2
flaB_UT2_F1
ACACCAGCRTCR
24








CTTTCAGG











flaB_UT2_F2
ACACCAGCATCA
25









YTAKCTGGA












flaB_UT2_F3
ACACCAGCATCA
26








TTRGCTGGA











flaB_UT2_R1
TTGGAAAGCACC
27








TAAATTTGCYCTT











flaB_UT2_R2
TTGRAAAGCACC
28








AAGATTTGCTCTT











flaB_UT2_R3
TTGGAAAGCACC
29









YAAATTTGCTCTT







Species
non-
glpQ
Sequence-based
glpQ_UT1
glpQ_UTI_F1
CCAGAACATACC
30


ID

Burgdorferi





TTAGAAKCTAAA





Borrelia





GC




spp
















glpQ_UTI_F2
CAGAACATACAT
31








TAGAAGCCAAAG









C











glpQ_UTI_R1
CCTTGTTGYTTAT
32








GCCATAAKGGTT











glpQ_UTI_R2
CCTTGTTGTTTAT
33








GCCAHAAGGGTT










glpQ-
glpQ-
CCAGAACATACC
34






Halp_UT2
Halp_UT2_F1
TTAGAAKCTAAA









GC











glpQ-
CAGAACATACAT
35







Halp_UT2_F2
TAGAAGCCAAAG









C











glpQ-
CACATTAGCAGA
36







Halp_UT2_R1
AATCAAATCAC











glpQ-
GATCAAATCTTT
37







Halp_UT2_R2
CGCTAAGRCTTA









GTG











glpQ-
GATCAAATCTTT
38







Halp_UT2_R3
CACTGAGACTTA









GTG











glpQ-
GATCAAATCTTT
39







Halp_UT2_R4
CACTAAGGCTTA









ATG











glpQ-
GGGTATCCARGG
40







Halp_UT2_R5
TCCAAT






Species

B.

bbk32
presence/absence
bbk32_UT
bbk32_UT_F1
TGGAGGAGMCTA
41


ID

burgdorferi





TTGAAAGYAATG




sensu stricto














Also good RNA

bbk32_UT_F2
TGAAGGAKACTA
42





target


TTGAAAGYAATG











bbk32_UT_R1
GCGTGTAGAATA
43








CATTTGGGTTAG









C











bbk32_UT_R2
GACGTGTAGAAT
44








ACATTTGGGTTT









GC






Species

B.

dbpA
presence/absence
dbpA_UT
dbpA_UT_F
AACAATGTAAAT
45


ID

burgdorferi





TTTGCTGCCTTT









Also good RNA

dbpA_UT_R
CCTGAGACCTCA
46





target


AGCATCAT






Species

B.

dbpB
presence/absence
dbpB_UT
dbpB_UT_F
CGGTTCCAAGGT
47


ID

burgdorferi





AACAAGTG









Also good RNA

dbpB_UT_R
TAATCCAATACT
48





target


ACATGCGACCAA









TA






Species

B.

dbpA
presence/absence
dbpA_UT2
dbpA_UT2_F1
CAGCCGCATCTG
233


ID

burgdorferi





TAACTG











dbpA_UT2_F2
TCAGTTCCCATTG
234








AAACTG











dbpA_UT2_F3
TTYAGCYGCATC
235








TGAGAC











dbpA_UT2_F4
TTCAGCTGCCWT
236








TGAGAC











dbpA_UT2_R1
CAGGYAGCAAGG
237








TATCAGA











dbpA_UT2_R2
CRGGTAGYGGGG
238








TATCAGA











dbpA_UT2_R3
AACAGGTRGAAA
239








GGYAGCA






Species

B.

dbpB
presence/absence
dbpB_UT2
dbpB_UT2_F1
CGCAAGCAATCT
240


ID

burgdorferi





TTCAGYTGTGT











dbpB_UT2_F2
CTCAACCAATCT
241








TTCAGCYGTGT











dbpB_UT2_F3
CTTCAAGCAATC
242








TTTCACATGTGT











dbpB_UT2_F4
CCTCAATTAATCT
243








TTCAGATGTGCT











dbpB_UT2_F5
TTCAAGCAATCT
244








TTCGGCTGTGT











dbpB_UT2_F6
CTCCATTACTCTT
245








TCGGCTGTGT











dbpB_UT2_R1
RYAGCKCTTGAA
246








TCRTCYTYTAAG









G











dbpB_UT2_R2
AAGCAATGCTTG
247








AATCSTMTTCTG









A











dbpB_UT2_R3
AAGCAAAGCTTG
248








AATCGTCTTCC






Species

Anaplasma

msp2
presence/absence
Ana-
Ana-
AGTTTGACTGGA
49


ID

phagocyto-

(major

msp2_UT1
msp2_UT1_F
ACACWCCTGATC





philum

surface









protein)









AY151054


Ana-
CTCGTAACCAAT
50







msp2_UT1_R
CTCAAGCTCAAC






Species

Anaplasma

msp2
presence/absence
Ana-
Ana-
GGGAGAGTAACG
51


ID

phagocyto-

(major

msp2_UT2
msp2_UT2_F
GAGARACWAAG





philum

surface



G





protein)















Ana-
CTGGCACCACCA
52







msp2_UT2_R1
ATACCATAACC











Ana-
CTGGCACCACCA
53







msp2_UT2_R2
ATACCRTACC











Ana-
GGGAGAGTAACG
54







msp2_UT2_F
GAGARACWAAG









G











Ana-
CTCGTAACCAAT
55







msp2_UT1_R
CTCAAGCTCAAC






Species

Ehrlichia

16S
presence indicates
Ehrl-_16S_UT
EhrI-16S_
GAGGATTTTATC
56


ID
genus

genus present

UT_F
TTTGTATTGTAGC









TAAC









sequence tells

Ehrl-
TGTAAGGTCCAG
57





species

16S_UT_R
CCGAACTGACT






Species

Ehrlichia

sodB
presence/absence
Ehrl-sodB_UT
Ehrl-
TTTAATAATGCT
58


ID
genus



sodB_UT_F
GGTCAAGTATGG









AATCAT









sequence-based to

Ehrl-
AAGCRTGYTCCC
59





tell species

sodB_UT_R
ATACATCCATAG






Species

B.

ospB
presence/absence
ospB_UT_1
ospB_UT_F1
TGCGGTGACAGA
60


ID

burgdorferi





AGACTC











ospB_UT_R1
CAGCAGAAACTG
61








TTAATTTTACTTT









ACTC









presence/absence
ospB_UT_2
ospB_UT_F2
TGCGGTGACAGA
62








AGACTC











ospB_UT_R2
AATCAGCAGAAA
63








CTGTTAATTTTAC









TTTAC






Species

B.

ospB
presence/absence
ospB_UT3
ospB_UT3_F1
GTYGAACTTAAA
249


ID

burgdorferi





GGAACTTCCGAT











ospB_UT3_F2
NTTGAGCTWAAA
250








GGAACWTCTGAT











ospB_UT3_F3
GTTGAGCTTAAA
251








GGRGTTKCTGA











ospB_UT3_F4
GGTGAGCTTAAA
252








GGGGATTTTGA











ospB_UT3_F5
GTTGAGCTTAAA
253








GGCCTTTCTGAG











ospB_UT3_R1
CCGMCTMCAAG
254








ACTTCCTTCA











ospB_UT3_R2
CCGCCTACAAGA
255








TTTCCTGGA











ospB_UT3_R3
CCACCAACAAGA
256








CTTCCTTCTAGT











ospB_UT3_R4
CCACCAACTAGA
257








CTTCCTTTAAAC











ospB_UT3_R5
CCACCAACAAGA
258








TTTCCTTCGAAC











ospB_UT3_R6
CATTAGCTACTTT
259








TCCTTCAAGAG











ospB_UT3_R7
CATTAGCTAGAG
260








TTCCTTCAAGAG











ospB_UT3_R8
TCAGCAGYTAGA
261








GTTCCTTCAAGA






Species

B.

ospC-TG
presence/absence
ospC-TG_UT1
ospC-
TCAGGRAAAGAT
262


ID

burgdorferi




TG_UT1_F
GGGAATRCATCT









GC











ospC-
GRCTTGTAAGCT
263







TG_UT1_R
CTTTAACTGMAT









TAG






Species

B.

p66
presence/absence
p66_UT3
p66_UT3_F1
GCCYATGACYGG
264


ID

burgdorferi





ATTCAAA











p66_UT3_F2
TTYGCACCTATG
265








ACTGGRTTT











p66_UT3_R
GGYTTCCATGTT
266








GCTTGAAY










p66_UT4
p66_UT4_F1
TGARGCTATCCA
267








TCCAAGRCC











p66_UT4_F2
GAAGCTGTCCAT
268








CCAAGATTAG











p66_UT4_R1
CGGTTTAGCTTG
269








GAATACAGATGA











p66_UT4_R2
CGGTTTTGCCTG
270








GAATAAAGATGA











p66_UT4_R3
GGCYTAGCTTGG
271








AAYATAGATGA










p66_UT5
p66_UT5_F
GCAATMGGAAA
272








YTCAACATTC











p66_UT5_R
CRCTTGCAAATG
273








GGTCTATTCCT






Species

B.

ospA
ospA
ospA_UT1
ospA_UT1_F1
GGITCTGGAAYA
274


ID

burgdorferi





CTTGAAGG











ospA_UT1_F2
GGATCTGGRRTR
275








CTTGAAGG











ospA_UT1_F3
GGTTCTGGAASC
276








CTTGARGG











ospA_UT1_F4
GGRYCTGGGGTR
277








CTTGAAGG











ospA_UT1_F5
GGATCTGGGGGA
278








AAGCTTGAAG











ospA_UT1_F6
GGTTCTGGDGTR
279








CTKGAAGG











ospA_UT1_F7
GGATCTGGMWH
280








GCYYGAAGG











ospA_UT1_F8
GGMGCTGGAMA
281








WCTTGAAGG











ospA_UT1_R1
CAAGTYTGKTKC
282








CRTTTKCTCTTG











ospA_UT1_R2
CAAGYYTGGTWC
283








CGTYTGCTCTTR











ospA_UT1_R3
CMAGTGTAGTYC
284








CGYTTGDTCTTG











ospA_UT1_R4
CAAGTMTKGWW
285








CCRTTTGCTCTTR











ospA_UT1_R5
CAAGKGTAGTTT
286








CGTTTKCTCTTG











ospA_UT1_R6
CAAKTGTAGTAT
287








YRTTTGATCTTG











ospA_UT1_R7
CAAGMKTRGTKC
288








CGTTTGCTCTTG











ospA_UT1_R8
CAAGTCTGGTTC
289








CGTCTTTTCTTG











ospA_UT1_R9
CAAGTGGTGTTC
290








CGTTTGTTCTTG











ospA_UT1_R10
CAAGTCTATTTCC
291








ATTTGCTCTTG











ospA_UT1_R11
CAAGTCTGGTTC
292








CGTTAYCTCTTA











ospA_UT1_R12
CAAGTCTGGTTC
293








CATTTGCCCTTA






Species

B.

ospC
presence/absence
ospC-
ospC-
ATGAAAAAGAAT
64


ID

burgdorferi



Bunikis_UT1
Bunikis_UT1_F
ACATTAAGTGC






Also


and sequence-based

ospC-
ATTAATCTTATA
65


typing




Bunikis_UT1
ATATTGATTTTAA



info




R
TTAAGG









presence/absence
ospC-
ospC-
TATTAATGACTTT
66






Bunikis_UT2
Bunikis_UT2_F
ATTTTTATTTATA









TCT









and sequence-based

ospC-
TTGATTTTAATTA
67







Bunikis_UT2
AGGTTTTTTTGG








R










presence/absence
ospC-
ospC-
AAAGAATACATT
68






Wang_UT1
Wang_UT1_F
AAGTGCGATATT









and sequence-based

ospC-
GGGCTTGTAAGC
69







VVang_UT1_R
TCTTTAACT






Species

B.

p66
presence/absence
p66-
p66-
GATTTTTCTATAT
70


ID

burgdorferi



Bunikis_UT1
Bunikis_UT1_F
TTGGACACAT









Also good RNA

p66-
TGTAAATCTTATT
71





target

Bunikis_UT1_
AGTTTTTCAAG








R










presence/absence
p66-
p66-
CAAAAAAGAAAC
72






Bunikis_UT2
Bunikis_UT2_F
ACCCTCAGATCC









Also good RNA

p66-
CCTGTTTTTAAAT
73





target

Bunikis_UT2_R
AAATTTTTGTAG









CATC









presence/absence
p66-
p66-
CGAAGATACTAA
74






Rudenko_UT1
Rudenko_UT1_F
ATCTGT









Also good RNA

p66-
GCTGCTTTTGAG
75





target

Rudenko_UT1_R
ATGTGTCC






Species

B.

ospA
presence/absence
ospA-
ospA-
GAGCTTAAAGGA
76


ID

burgdorferi



Rudenko_UT
Rudenko_UT_F
ACTTCTGATAA











ospA-
GTATTGTTGTACT
77







Rudenko_UT_R
GTAATTGT






Differen-
Enterovirus
VP1
presence/absence
EV-D68_UT
EV-
ACCAGARGAAGC
78


tial
strain D68



D68_UT_F1
CATACAAAC



diagnos-









tic

















EV-
TGACACTTCAAG
79







D68_UT_F2
CAATGTTCGTA











EV-
AACGCCGAACTT
80







D68_UT_F3
GGTGTG











EV-
AACACCGAACCA
81







D68_UT_F4
GAGGAAG











EV-
SCTGAYTGCCAR
82







D68_UT_R1
TGGAATGAA











EV-
ATGTGCTGTTATT
83







D68_UT_R2
GCTACCTACTG











EV-
ATTATTACTACTA
84







D68_UT_R3
CCATTCACTGCT









ACA











EV-
TCAAATCCAGCA
85







D68_UT_R4
AAGCCATCA











EV-
AGAATACACTAG
86







D68_UT_R5
CATTACTACCTG









ACT






Differen-

Staphylo-



Sa_M4_UT2
Sa_M4_UT2_F
TAGCGTTGGTAT
87


tial

coccus





TAAGTGGTTGT



diagnos-

aureus









tics

















Sa_M4_UT2_R
GTCATAGCATAG
88








TTCGGGTCA






Differen-
Influenza
matrix gene
presence/absence
H3N2_UT
H3N2_UT_F
AAGACCAATYCT
89


tial





GTCACCTCTGA



diagnos-









tics















RNA target

H3N2_UT_R
CAAAGCGTCTAC
90








GCTGCAGTCC






Differen-

Yersinia

plasmid

Yppla_UT
Yppla_UT_F
GAAAGGAGTGCG
91


tial

pestis





GGTAATAGGTT



diagnos-









tics

















Yppla_UT_R
GGCCTGCAAGTC
92








CAATATATGG








chromosome

Yp3a_UT
Yp3a_UT_F
CATTGGACGGCA
93








TCACGAT











Yp3a_UT_R
AGTTGGCCAGCG
94








ATTCGA






Differen-

Francisella


SNP
Ft-G_UT
Ft-G_UT_F
CTAAGCCATAAG
95


tial

tularensis





CCCTTTCTCTAAC



diagnos-





TTGT



tics

















Ft-G_UT_R
AGCAATGACAAA
96








GCTTGTTGAAAA









AG






Species

Borrelia

porin gene
presence/absence
p66-
p66_UT1_F
GTAATTGCAGAA
97


ID

burgdorferi



borrelia_UT1

ACACCTTTTGAA









T











p66_UT1_R
CTGCTTTTGAGAT
98








GTGTCCAA









presence/absence
p66-
p66_UT2_F
TGTAATTGCAGA
99






borrelia_UT2

AACACCTTTTGA











p66_UT2_R
gctgcttttgag
100








ATGTGTCC






Species

outer
presence/absence
ospD-
ospD_UT1_F
ATCAWMTGAGG
101


ID

surface

borrelia_UT1

CAAATAAAGTTG





protein D



TAGA











ospD_UT1_R
TGTTCTGCYGCTT
102








TAGTAAGG






Species

Borrelia

partitioning
presence/absence
par_A_UT1
par_A_UT1_F
TTRACTTCTTCTA
103


ID

burgdorferi

gene



TYGCATCCATTA











par_A_UT1_R
TRTTCCTTCTCAT
104








CCAATTCTATGT






Genus ID

Bartonella

ssrA
presence/absence
Bart-ssrA_UT1
Bart-
GGCTAAATIAGTA
105







ssrA_UT1_F
GTTGCAAAYGAC









A











Bart-
GCTTCTGTTGCCA
106







ssrA_UT1_R
GGTG






Genus ID

Babesia

18S
sequence-based
Babe-18S_UT1
Babe-
ACCGTCCAAAGC
107







18S_UT1_F
TGATAGGTC











Babe-
CGAAACTGCGAA
108







18S_UT1_R
TGGCTCATTA






Genus ID

Rickettsia

ompA
presence/absence
Rkttsia-
Rkttsia-
GGCATTTACTTA
294






ompA_UT1
ompA_UT1_F
CRGTGSTGAT








Rkttsia-
CCATGATTTGCA
295







ompA_UT1_R
GCAAYAGCAT










Rkttsia-
Rkttsia-
CGYTAGCTGGGC
296






ompA_UT2
ompA_UT2_F
TTAGRTATTC











Rkttsia-
CGCCGRAACTTT
297







ompA_UT2_R
ATTCTTGAATG










Rkttsia-
Rkttsia-
ACTTAYGGTGGT
298






ompA_UT3
ompA_UT3_F
GATTATAYTATC











Rkttsia-
TGCAGCAACAGC
299







ompA_UT3_R
ATTAKTACYG










Rkttsia-
Rkttsia-
GCTGRAGGAGTA
300






ompA_UT4
ompA_UT4_F1
GCTAATGGT











Rkttsia-
GCAGCAGGAGTA
301







ompA_UT4_F2
GCTGATGAT











Rkttsia-
MCGCAGCAGTAC
302







ompA_UT4_R
CGGTTAAAG










Rkttsia-
Rkttsia-
CAACCGCAGCRW
303






ompA_UT5
ompA_UT5_F
TAATGCTAAC











Rkttsia-
CCTCCCGTATCTA
304







ompA_UT5_R
CCACTGAAC










Rkttsia-
Rkttsia-
TGCAGGAGCAGA
305






ompA_UT6
ompA_UT6_F
TAATGGTA











Rkttsia-
GCCGGCAGTAAT
306







ompA_UT6_R
AGTAACAG










Rkttsia-
Rkttsia-
GGTGCAAGCCAA
307






ompA_UT7
ompA_UT7_F1
GTAACATATAC











Rkttsia-
AGGTACAAATCA
308







ompA_UT7_F2
AGTAACATATAC









C











Rkttsia-
AAACCGCCTTCC
309







ompA_UT7_R1
GTTTCTG











Rkttsia-
AATCCACCTGCC
310







ompA_UT7_R2
GCTTCTG






Genus ID
Powassan

presence/absence
Powass_UT
Powass_UT_F1
GGCDGTAGGYCA
311



and deer




TGTTTATGAC




tick viruses
















Powass_UT_F2
AGCTGTGGGCCA
312








CGTCTATGAC











Powass_UT_R1
CCGAAGGCAGGT
313








GATCTTTG











Powass_UT_R2
CAGAAGGCAGGT
314








GGTCCTTG






Internal
Human
gapDH
presence/absence
IPC-
IPC-
CCTGCCAAATAT
109


control



gapDH_UT1
gapDH_UT1_F
GATGACATCAAG











IPC-
GTGGTCGTTGAG
110







gapDH_UT1_R
GGCAATG
















TABLE 2







Primers for LymeSeq Lyme Disease


Next-Generation Sequencing


Diagnostic Assay with the universal


tail targets. ACCCAACTGAATGGAGC


(SEQ ID NO: 217) or


ACGCACTTGACTTGTCTTC (SEQ ID NO: 218).










Sequence with
SEQ



Universal Tail
ID


Primer
Target
NO:












16S-1_UT_F
ACCCAACTGA
111



ATGGAGCCGG




GTGAGTAACG




CGTGGAT






16S-1_UT_R
ACGCACTTGA
112



CTTGTCTTCC




CTCTCAGGCC




GGTTACTTAT




C






16S-2_UT_F
ACCCAACTGA
113



ATGGAGCCGG




TCACACTGGA




ACTGAGA






16S-2_UT_R
ACGCACTTGA
114



CTTGTCTTCG




CTGCTGGCAC




GTAATTAGC






16S-3_UT_F
ACCCAACTGA
115



ATGGAGCGCG




AGCGTTGTTC




GGGAT






16S-3_UT_R
ACGCACTTGA
116



CTTGTCTTCA




CTCAGCGTCA




GTCTTGACC






16S-4_UT_F
ACCCAACTGA
117



ATGGAGCCGC




TGTAAACGAT




GCACACTTG






16S-4_UT_R
ACGCACTTGA
118



CTTGTCTTCA




CAACCATGCA




GCACCTGTA






16S-5_UT_F
ACCCAACTGA
119



ATGGAGCGCA




ACGAGCGCAA




CCCTT






16S-5_UT_R
ACGCACTTGA
120



CTTGTCTTCT




ACAAGGCCCG




AGAACGTATT




CAC






Ana-msp2_UT1_F
ACCCAACTGA
121



ATGGAGCAGT




TTGACTGGAA




CACWCCTGAT




C






Ana-msp2_UT1_R
ACGCACTTGA
122



CTTGTCTTCC




TCGTAACCAA




TCTCAAGCTC




AAC






Ana-msp2_UT2_F
ACCCAACTGA
123



ATGGAGCGGG




AGAGTAACGG




AGARACWAAG




G






Ana-msp2_UT2_R1
ACGCACTTGA
124



CTTGTCTTCC




TGGCACCACC




AATACCATAA




CC






Ana-msp2_UT2_R2
ACGCACTTGA
125



CTTGTCTTCC




TGGCACCACC




AATACCRTAC




C






Babe-18S_UT1_F
ACCCAACTGA
126



ATGGAGCACC




GTCCAAAGCT




GATAGGTC






Babe-18S_UT1_R
ACGCACTTGA
127



CTTGTCTTCC




GAAACTGCGA




ATGGCTCATT




A






Bart-ssrA_UT1_F
ACCCAACTGA
128



ATGGAGCGGC




TAAATTAGTA




GTTGCAAAYG




ACA






Bart-ssrA_UT1_R
ACGCACTTGA
129



CTTGTCTTCG




CTTCTGTTGC




CAGGTG






bbk32_UT_F1
ACCCAACTGA
130



ATGGAGCTGG




AGGAGMCTAT




TGAAAGYAAT




G






bbk32_UT_F2
ACCCAACTGA
131



ATGGAGCTGA




AGGAKACTAT




TGAAAGYAAT




G






bbk32_UT_R1
ACGCACTTGA
132



CTTGTCTTCG




CGTGTAGAAT




ACATTTGGGT




TAGC






bbk32_UT_R2
ACGCACTTGA
133



CTTGTCTTCG




ACGTGTAGAA




TACATTTGGG




TTTGC






dbpA_UT_F
ACCCAACTGA
134



ATGGAGCAAC




AATGTAAATT




TTGCTGCCTT




T






dbpA_UT_R
ACGCACTTGA
135



CTTGTCTTCC




CTGAGACCTC




AAGCATCAT






dbpB_UT_F
ACCCAACTGA
136



ATGGAGCCGG




TTCCAAGGTA




ACAAGTG






dbpB_UT_R
ACGCACTTGA
137



CTTGTCTTCT




AATCCAATAC




TACATGCGAC




CAATA






Ehrl-16S_UT_F
ACCCAACTGA
138



ATGGAGCGAG




GATTTTATCT




TTGTATTGTA




GCTAAC






Ehrl-16S_UT_R
ACGCACTTGA
139



CTTGTCTTCT




GTAAGGTCCA




GCCGAACTGA




CT






Ehrl-sodB_UT_F
ACCCAACTGA
140



ATGGAGCTTT




AATAATGCTG




GTCAAGTATG




GAATCAT






Ehrl-sodB_UT_R
ACGCACTTGA
141



CTTGTCTTCA




AGCRTGYTCC




CATACATCCA




TAG






EV-D68_UT_F1
ACCCAACTGA
142



ATGGAGCACC




AGARGAAGCC




ATACAAAC






EV-D68_UT_F2
ACCCAACTGA
143



ATGGAGCTGA




CACTTCAAGC




AATGTTCGTA






EV-D68_UT_F3
ACCCAACTGA
144



ATGGAGCAAC




GCCGAACTTG




GTGTG






EV-D68_UT_F4
ACCCAACTGA
145



ATGGAGCAAC




ACCGAACCAG




AGGAAG






EV-D68_UT_R1
ACGCACTTGA
146



CTTGTCTTCS




CTGAYTGCCA




RTGGAATGAA






EV-D68_UT_R2
ACGCACTTGA
147



CTTGTCTTCA




TGTGCTGTTA




TTGCTACCTA




CTG






EV-D68_UT_R3
ACGCACTTGA
148



CTTGTCTTCA




TTATTACTAC




TACCATTCAC




TGCTACA






EV-D68_UT_R4
ACGCACTTGA
149



CTTGTCTTCT




CAAATCCAGC




AAAGCCATCA






EV-D68_UT_R5
ACGCACTTGA
150



CTTGTCTTCA




GAATACACTA




GCATTACTAC




CTGACT






flaB_UT1_F
ACCCAACTGA
151



ATGGAGCGCW




TCTGATGATG




CTGCTGGTA






flaB_UT1_R1
ACGCACTTGA
152



CTTGTCTTCG




CATTCCAAGY




TCTTCAGCTG




T






flaB_UT1_R2
ACGCACTTGA
153



CTTGTCTTCG




CATTCCAAGC




TCTTCAGCWG




T






flaB_UT2_F1
ACCCAACTGA
154



ATGGAGCACA




CCAGCRTCRC




TTTCAGG






flaB_UT2_F2
ACCCAACTGA
155



ATGGAGCACA




CCAGCATCAY




TAKCTGGA






flaB_UT2_F3
ACCCAACTGA
156



ATGGAGCACA




CCAGCATCAT




TRGCTGGA






flaB_UT2_R1
ACGCACTTGA
157



CTTGTCTTCT




TGGAAAGCAC




CTAAATTTGC




YCTT






flaB_UT2_R2
ACGCACTTGA
158



CTTGTCTTCT




TGRAAAGCAC




CAAGATTTGC




TCTT






flaB_UT2_R3
ACGCACTTGA
159



CTTGTCTTCT




TGGAAAGCAC




CYAAATTTGC




TCTT






Ft-G_UT_F
ACCCAACTGA
160



ATGGAGCCTA




AGCCATAAGC




CCTTTCTCTA




ACTTGT






Ft-G_UT_R
ACGCACTTGA
161



CTTGTCTTCA




GCAATGACAA




AGCTTGTTGA




AAAAG






glpQ_UT1_F1
ACCCAACTGA
162



ATGGAGCCCA




GAACATACCT




TAGAAKCTAA




AGC






glpQ_UT1_F2
ACCCAACTGA
163



ATGGAGCCAG




AACATACATT




AGAAGCCAAA




GC






glpQ_UT1_R1
ACGCACTTGA
164



CTTGTCTTCC




CTTGTTGYTT




ATGCCATAAK




GGTT






glpQ_UT1_R2
ACGCACTTGA
165



CTTGTCTTCC




CTTGTTGTTT




ATGCCAHAAG




GGTT






glpQ-Halp_UT2_F1
ACCCAACTGA
166



ATGGAGCCCA




GAACATACCT




TAGAAKCTAA




AGC






glpQ-Halp_UT2_F2
ACCCAACTGA
167



ATGGAGCCAG




AACATACATT




AGAAGCCAAA




GC






glpQ-Halp_UT2_R1
ACGCACTTGA
168



CTTGTCTTCC




ACATTAGCAG




AAATCAAATC




AC






glpO-Halp_UT2_R2
ACGCACTTGA
169



CTTGTCTTCG




ATCAAATCTT




TCGCTAAGRC




TTAGTG






glpQ-Halp_UT2_R3
ACGCACTTGA
170



CTTGTCTTCG




ATCAAATCTT




TCACTGAGAC




TTAGTG






glpQ-Halp_UT2_R4
ACGCACTTGA
171



CTTGTCTTCG




ATCAAATCTT




TCACTAAGGC




TTAATG






glpQ-Halp_UT2_R5
ACGCACTTGA
172



CTTGTCTTCG




GGTATCCARG




GTCCAAT






H3N2_UT_F
ACCCAACTGA
173



ATGGAGCAAG




ACCAATYCTG




TCACCTCTGA






H3N2_UT_R
ACGCACTTGA
174



CTTGTCTTCC




AAAGCGTCTA




CGCTGCAGTC




C






IGS1-Bunikis_UT1_F
ACCCAACTGA
175



ATGGAGCGTA




TGTTTAGTGA




GGGGGGTG






IGS1-Bunikis_UT1_R
ACGCACTTGA
176



CTTGTCTTCG




GATCATAGCT




CAGGTGGTTA




G






IGS1-Bunikis_UT2_F
ACCCAACTGA
177



ATGGAGCAGG




GGGGTGAAGT




CGTAACAAG






IGS1-Bunikis_UT2_R
ACGCACTTGA
178



CTTGTCTTCG




TCTGATAAAC




CTGAGGTCGG




A






IGS2-Derdakova_UT_F
ACCCAACTGA
179



ATGGAGCCGA




CCTTCTTCGC




CTTAAAGC






IGS2-Derdakova_UT_R
ACGCACTTGA
180



CTTGTCTTCA




GCTCTTATTC




GCTGATGGTA






IGS-5S-23S-Postic_UT_F
ACCCAACTGA
181



ATGGAGCCTG




CGAGTTCGCG




GGAGA






IGS-5S-23S-Postic_UT_R
ACGCACTTGA
182



CTTGTCTTCT




CCTAGGCATT




CACCATA






IGS-5S-23S-TK_UT_F
ACCCAACTGA
183



ATGGAGCGAG




TTCGCGGGAG




AGTAGGTTAT




TGCC






IGS-5S-23S-TK_UT_R
ACGCACTTGA
184



CTTGTCTTCT




CAGGGTACTT




AGATGKTTCA




CTTCC






IPC-gapDH_UT1_F
ACCCAACTGA
185



ATGGAGCCCT




GCCAAATATG




ATGACATCAA




G






IPC-gapDH_UT1_R
ACGCACTTGA
186



CTTGTCTTCG




TGGTCGTTGA




GGGCAATG






ospA-Rudenko_UT_F
ACCCAACTGA
187



ATGGAGCGAG




CTTAAAGGAA




CTTCTGATAA






ospA-Rudenko_UT_R
ACGCACTTGA
188



CTTGTCTTCG




TATTGTTGTA




CTGTAATTGT






ospB_UT1_F
ACCCAACTGA
189



ATGGAGCTGC




GGTGACAGAA




GACTC






ospB_UT1_R
ACGCACTTGA
190



CTTGTCTTCC




AGCAGAAACT




GTTAATTTTA




CTTTACTC






ospB_UT2_F
ACCCAACTGA
191



ATGGAGCTGC




GGTGACAGAA




GACTC






ospB_UT2_R
ACGCACTTGA
192



CTTGTCTTCA




ATCAGCAGAA




ACTGTTAATT




TTACTTTAC






ospC-Bunikis_UT1_F
ACCCAACTGA
193



ATGGAGCATG




AAAAAGAATA




CATTAAGTGC






ospC-Bunikis_UT1_R
ACGCACTTGA
194



CTTGTCTTCA




TTAATCTTAT




AATATTGATT




TTAATTAAGG






ospC-Bunikis_UT2_F
ACCCAACTGA
195



ATGGAGCTAT




TAATGACTTT




ATTTTTATTT




ATATCT






ospC-Bunikis_UT2_R
ACGCACTTGA
196



CTTGTCTTCT




TGATTTTAAT




TAAGGTTTTT




TTGG






ospC-Wang_UT1_F
ACCCAACTGA
197



ATGGAGCAAA




GAATACATTA




AGTGCGATAT




T






ospC-Wang_UT1_R
ACGCACTTGA
198



CTTGTCTTCG




GGCTTGTAAG




CTCTTTAACT






ospD_UT1_F
ACCCAACTGA
199



ATGGAGCGAG




CTTAAAGGAA




CTTCTGATAA






ospD_UT1_R
ACGCACTTGA
200



CTTGTCTTCG




TATTGTTGTA




CTGTAATTGT






p66_UT1_F
ACCCAACTGA
201



ATGGAGCGAG




CTTAAAGGAA




CTTCTGATAA






p66_UT1_R
ACGCACTTGA
202



CTTGTCTTCG




TATTGTTGTA




CTGTAATTGT






p66_UT2_F
ACCCAACTGA
203



ATGGAGCGAG




CTTAAAGGAA




CTTCTGATAA






p66_UT2_R
ACGCACTTGA
204



CTTGTCTTCG




TATTGTTGTA




CTGTAATTGT






p66-Bunikis_UT1_F
ACCCAACTGA
205



ATGGAGCGAT




TTTTCTATAT




TTGGACACAT






p66-Bunikis_UT1_R
ACGCACTTGA
206



CTTGTCTTCT




GTAAATCTTA




TTAGTTTTTC




AAG






p66-Bunikis_UT2_F
ACCCAACTGA
207



ATGGAGCCAA




AAAAGAAACA




CCCTCAGATC




C






p66-Bunikis_UT2_R
ACGCACTTGA
208



CTTGTCTTCC




CTGTTTTTAA




ATAAATTTTT




GTAGCATC






p66-Rudenko_UT1_F
ACCCAACTGA
209



ATGGAGCCGA




AGATACTAAA




TCTGT






p66-Rudenko_UT1_R
ACGCACTTGA
210



CTTGTCTTCG




CTGCTTTTGA




GATGTGTCC






par_A_UT1_F
ACCCAACTGA
211



ATGGAGCGAG




CTTAAAGGAA




CTTCTGATAA






par_A_UT1_R
ACGCACTTGA
212



CTTGTCTTCG




TATTGTTGTA




CTGTAATTGT






Yp3a_UT_F
ACCCAACTGA
213



ATGGAGCCAT




TGGACGGCAT




CACGAT






Yp3a_UT_R
ACGCACTTGA
214



CTTGTCTTCA




GTTGGCCAGC




GATTCGA






Yppla_UT_F
ACCCAACTGA
215



ATGGAGCGAA




AGGAGTGCGG




GTAATAGGTT






Yppla_UT_R
ACGCACTTGA
216



CTTGTCTTCG




GCCTGCAAGT




CCAATATATG




G
















TABLE 3







Additional primers for LymeSeq Lyme Disease Next-Generation Sequencing Diagnostic Assay with


the universal tail targets ACCCAACTGAATGGAGC (SEQ ID NO: 217)


or ACGCACTTGACTTGTCTTC (SEQ ID NO: 218)





















SEQ


Target
Target
Target Gene/
LIT Assay



ID


Purpose
Taxon
Region
Type
Assay
Primer
Sequence with UT
NO:

















Species

Borrelia

16S-set of 5
Sequence-
I6S-1_UT
16S-1_UT_F
ACCCAACTGAATGG
315


ID
spp.
assays to cover
based


AGCCGGGTGAGTA





whole gene



ACGCGTGGAT











16S-1_UT_R
ACGCACTTGACTTG
316








TCTTCCCTCTCAGG









CCGGTTACTTATC










16S-2_UT
16S-2_UT_F
ACCCAACTGAATGG
317








AGCCGGTCACACTG









GAACTGAGA











16S-2_UT_R
ACGCACTTGACTTG
318








TCTTCGCTGCTGGC









ACGT AATTAGC










16S-3_UT
16S-3_UT_F
ACCCAACTGAATGG
319








AGCGCGAGCGTTGT









TCGGGAT











I6S-3_UT_R
ACGCACTTGACTTG
320








TCTTCACTCAGCGT









CAGTCTTGACC










16S-4_UT
16S-4_UT_F
ACCCAACTGAATGG
321








AGCCGCTGTAAACG









ATGCACACTTG











16S-4_UT_R
ACGCACTTGACTTG
322








TCTTCACAACCATG









CAGCACCTGTA










16S-5_UT
16S-5_UT_F
ACCCAACTGAATGG
323








AGCGCAACGAGCG









CAACCCTT











16S-5_UT_R
ACGCACTTGACTTG
324








TCTTCTACAAGGCC









CGAGAACGTATTCA









C






Species

Borrelia

IGS2 5S-23S
Sequence-
IGS2-5S-23S-
IGS-5S-23S-
ACCCAACTGAATGG
325


ID
spp.

based
Postic_UT
Postic_UT_F
AGCCTGCGAGTTCG









CGGGAGA











IGS-5S-23S-
ACGCACTTGACTTG
326







Postic_UT_R
TCTTCTCCTAGGCA









TTCACCATA






Species

Borrelia

IGS rrs-rrlA

rrs-rrlA_UT1
rrs-
ACCCAACTGAATGG
327


ID
spp.
16S-23S IGS


rrlA_UT1_F1
AGCGGGTTCGAGTC









CCTYAACCT






new




rrs-
ACCCAACTGAATGG
328


assays




rrlA_UT1_F2
AGCTTGGTTTAGAG



062216





CATCGGCTTTGC











rrs-
ACGCACTTGACTTG
329







rrlA_UT1_R1
TCTTCCCTTGCACT









TTAGCGAAACAAC











rrs-
ACGCACTTGACTTG
330







rrlA_UT1_R2
TCTTCCCTTGTGCTT









TAGTGAAACAAC











rrs-
ACGCACTTGACTTG
331







rrlA_UT1_R3
TCTTCACTTGCCAT









ACGTAAACAACCGT











rrs-
ACGCACTTGACTTG
332







rrlA_UT1_R4
TCTTCCTCATGACT









TGTCACACGTAAAC









AAC











rrs-
ACGCACTTGACTTG
333







rrlA_UT1_R5
TCTTCGTTCAACTC









CTCCTGGTCCCAA











rrs-
ACGCACTTGACTTG
334







rrlA_UT1_R6
TCTTCATCCTATAG









ATGCAATCTCTTGW









CC











rrs-
ACGCACTTGACTTG
335







rrlA_UT1_R7
TCTTCTTTGCATGT









AATCAAGTCTTGGA









ATTC











rrs-
ACGCACTTGACTTG
336







rrlA_UT1_R8
TCTTCTACTTTCAC









CTCTAGACATTCTT









GT











rrs-
ACGCACTTGACTTG
337







rrlA_UT1_R9
TCTTCTAGGTTGAT









TCATGATCAGGTCC









TT











rrs-
ACGCACTTGACTTG
338







rrlA_UT1_R1
TCTTCCGATTCGGT








0
CACGGCTCTTAC











rrs-
ACGCACTTGACTTG
339







rrlA_UT1_R1
TCTTCCCTTATGAT








1
TTAGTAACACAACG









TAAGT











rrs-
ACGCACTTGACTTG
340







rrlA_UT1_R1
TCTTCAAGCTAGTA








2
ATGAATGTGGGATG









TT






Species

Borrelia

flaB
Sequence-
flaB_UT1
flaB_UT1_F
ACCCAACTGAATGG
341


ID
spp.

based


AGCGCWTCTGATG









ATGCTGCTGGIA











flaB_UT1_R1
ACGCACTTGACTTG
342








TCTTCGCATTCCAA









GYTCTTCAGCTGT











flaB_UT1_R2
ACGCACTTGACTTG
343








TCTTCGCATTCCAA









GCTCTTCAGCWGT










flaB_UT2
flaB_UT2_F1
ACCCAACTGAATGG
344








AGCACACCAGCRTC









RCTTTCAGG











flaB_UT2_F2
ACCCAACTGAATGG
345








AGCACACCAGCATC









AYTAKCTGGA











flaB_UT2_F3
ACCCAACTGAATGG
346








AGCACACCAGCATC









ATTRGCTGGA











flaB_UT2_R1
ACGCACTTGACTTG
347








TCTTCTTGGAAAGC









ACCTAAATTTGCYC









TT











flaB_UT2_R2
ACGCACTTGACTTG
348








TCTTCTTGRAAAGC









ACCAAGATTTGCTC









TT











flaB_UT2_R3
ACGCACTTGACTTG
349








TCTTCTTGGAAAGC









ACCYAAATTTGCTC









TT






Species
non-
glpQ
Sequence-
glpQ_UT1
glpQ_UT1_F1
ACCCAACTGAATGG
350


ID

Burgdorferi


based


AGCCCAGAACATA





Borrelia





CCTTAGAAKCTAAA




spp.




GC











glpQ_UT1_F2
ACCCAACTGAATGG
351








AGCCAGAACATAC









ATTAGAAGCCAAA









GC











glpQ_UT1_R1
ACGCACTTGACTTG
352








TCTTCCCTTGTTGY









TTATGCCATAAKGG









TT











glpO_UT1_R2
ACGCACTTGACTTG
353








TCTTCCCTTGTTGTT









TATGCCAHAAGGGT









T






Species

B.

bbk32
presence/
bbk32_UT
bbk32_UT_F1
ACCCAACTGAATGG
354


ID

burgdorferi


absence


AGCTGGAGGAGMC




ss




TATTGAAAGYAATG











bbk32_UT_F2
ACCCAACTGAATGG
355








AGCTGAAGGAKAC









TATTGAAAGYAATG











bbk32_UT_R1
ACGCACTTGACTTG
356








TCTTCGCGTGTAGA









ATACATTTGGGTTA









GC











bbk32_UT_R2
ACGCACTTGACTTG
357








TCTTCGACGTGTAG









AATACATTTGGGTT









TGC






Species

B.

dbpA
presence/
dbpA_UT2
dbpA_UT2_F1
ACCCAACTGAATGG
358


ID

burgdorferi


absence


AGCCAGCCGCATCT









GTAACTG











dbpA_UT2_F2
ACCCAACTGAATGG
359








AGCTCAGTTCCCAT









TGAAACTG











dbpA_UT2_F3
ACCCAACTGAATGG
360








AGCTTYAGCYGCAT









CTGAGAC











dbpA_UT2_F4
ACCCAACTGAATGG
361








AGCTTCAGCTGCC









WTTGAGAC











dbpA_UT2_R
ACGCACTTGACTTG
362







I
TCTTCCAGGYAGCA









AGGTATCAGA











dbpA_UT2_R
ACGCACTTGACTTG
363







2
TCTTCCRGGTAGYG









GGGTATCAGA











dbpA_UT2_R
ACGCACTTGACTTG
364







3
TCTTCAACAGGTRG









AAAGGYAGCA






Species

B.

dbpB
presence/
dbpB_UT2
dbpB_UT2_F1
ACCCAACTGAATGG
365


ID

burgdorferi


absence


AGCCGCAAGCAAT









CTTTCAGYTGTGT











dbpB_UT2_F2
ACCCAACTGAATGG
366








AGCCTCAACCAATC









TTTCAGCYGTGT











dbpB_UT2_F3
ACCCAACTGAATGG
367








AGCCTTCAAGCAAT









CTTTCACATGTGT











dbpB_UT2_F4
ACCCAACTGAATGG
368








AGCCCTCAATTAAT









CTTTCAGATGTGCT











dbpB_UT2_F5
ACCCAACTGAATGG
369








AGCTTCAAGCAATC









TTTCGGCTGTGT











dbpB_UT2_F6
ACCCAACTGAATGG
370








AGCCTCCATTACTC









TTTCGGCTGTGT











dbpB_UT2_R
ACGCACTTGACTTG
371







1
TCTTCRYAGCKCTT









GAATCRTCYTYTAA









GG











dbpB_UT2_R
ACGCACTTGACTTG
372







2
TCTTCAAGCAATGC









TTGAATCSTMTTCT









GA











dbpB_UT2_R
ACGCACTTGACTTG
373







3
TCTTCAAGCAAAGC









TTGAATCGTCTTCC






Species

Anaplasma

msp2 (major

Ana-
Ana-
ACCCAACTGAATGG
374


ID

phagocyto-

surface protein)

msp2_UT2
msp2_UT2_F
AGCGGGAGAGTAA





philum





CGGAGARACWAAG









G











Ana-
ACGCACTTGACTTG
375







msp2_UT2_R
TCTTCCTGGCACCA








1
CCAATACCATAACC











Ana-
ACGCACTTGACTTG
376







msp2_UT2_R
TCTTCCTGGCACCA








2
CCAATACCRTACC






Species

Ehrlichia

16S
Sequence-
Ehrl-16S_UT
Ehrl-
ACCCAACTGAATGG
377


ID
genus

based

16S_UT_F
AGCGAGGATTTTAT









CTTTGTATTGTAGC









TAAC











Ehrl-
ACGCACTTGACTTG
378







16S_UT_R
TCTTCTGTAAGGTC









CAGCCGAACTGACT






Species

Ehrlichia

16S
Sequence-
Ehrl-
Ehrl-
ACCCAACTGAATGG
379


ID
genus

based
16S_UT2
16S_UT2_F
AGCCAGGATTAGAT









ACCCTGGTAGTCCA











Ehrl-
ACGCACTTGACTTG
380







16S_UT2_R
TCTTCACGACACGA









GCTGACGACA






Species

Ehrlichia

sodB
presence/
Ehrl-
Ehrl-
ACCCAACTGAATGG
381


ID
genus

absence
sodB_UT
sodB_UT_F
AGCTTTAATAATGC









TGGTCAAGTATGGA









ATCAT











Ehrl-
ACGCACTTGACTTG
382







sodB_UT_R
TCTTCAAGCRTGYT









CCCATACATCCATA









G






Species

B.

ospB
presence/
ospB_UT3
ospB_UT3_F1
ACCCAACTGAATGG
383


ID

burgdorferi


absence


AGCGTYGAACTTAA









AGGAACTTCCGAT











ospB_UT3_F2
ACCCAACTGAATGG
384








AGCNTTGAGCTWA









AAGGAACWTCTGA









T











ospB_UT3_F3
ACCCAACTGAATGG
385








AGCGTTGAGCTTAA









AGGRGTTKCTGA











ospB_UT3_F4
ACCCAACTGAATGG
386








AGCGGTGAGCTTAA









AGGGGATTTTGA











ospB_UT3_F5
ACCCAACTGAATGG
387








AGCGTTGAGCTTAA









AGGCCTTTCTGAG











ospB_UT3_R1
ACGCACTTGACTTG
388








TCTTCCCGMCTMCA









AGACTTCCTTCA











ospB_UT3_R2
ACGCACTTGACTTG
389








TCTTCCCGCCTACA









AGATTTCCTGGA











ospB_UT3_R3
ACGCACTTGACTTG
390








TCTTCCCACCAACA









AGACTTCCTTCTAG









T











ospB_UT3_R4
ACGCACTTGACTTG
391








TCTTCCCACCAACT









AGACTTCCTTTAAA









C











ospB_UT3_R5
ACGCACTTGACTTG
392








TCTTCCCACCAACA









AGATTTCCTTCGAA









C











ospB_UT3_R6
ACGCACTTGACTTG
393








TCTTCCATTAGCTA









CTTTTCCTTCAAGA









G











ospB_UT3_R7
ACGCACTTGACTTG
394








TCTTCCATTAGCTA









GAGTTCCTTCAAGA









G











ospB_UT3_R8
ACGCACTTGACTTG
395








TCTTCTCAGCAGYT









AGAGTTCCTTCAAG









A






Species

B.

ospC-TG
presence/
ospC-
ospC-
ACCCAACTGAATGG
396


ID

burgdorferi


absence
TG_UT1
TG_UT1_F
AGCTCAGGRAAAG









ATGGGAATRCATCT









GC











ospC-
ACGCACTTGACTTG
397







TG_UT1_R
TCTTCGRCTTGTAA









GCTCTTTAACTGMA









TTAG






Species

B.

p66
presence/
p66_UT3
p66_UT3_F1
ACCCAACTGAATGG
398


ID

burgdorferi


absence


AGCGCCYATGACY









GGATTCAAA











p66_UT3_F2
ACCCAACTGAATGG
399








AGCTTYGCACCTAT









GACTGGRTTT











p66_UT3_R
ACGCACTTGACTTG
400








TCTTCGGYTTCCAT









GTTGCTTGAAY










p66_UT4
p66_UT4_F1
ACCCAACTGAATGG
401








AGCTGARGCTATCC









ATCCAAGRCC











p66_UT4_F2
ACCCAACTGAATGG
402








AGCGAAGCTGTCCA









TCCAAGATTAG











p66_UT4_R1
ACGCACTTGACTTG
403








TCTTCCGGTTTAGC









TTGGAATACAGATG









A











p66_UT4_R2
ACGCACTTGACTTG
404








TCTTCCGGTTTTGC









CTGGAATAAAGAT









GA











p66_UT4_R3
ACGCACTTGACTTG
405








TCTTCGGCYTAGCT









TGGAAYATAGATG









A










p66_UT5
p66_UT5_F
ACCCAACTGAATGG
406








AGCGCAATMGGAA









AYTCAACATTC











p66_UT5_R
ACGCACTTGACTTG
407








TCTTCCRCTTGCAA









ATGGGTCTATTCCT






Species

B.

ospA
ospA
ospA_UT1
ospA_UT1_F1
ACCCAACTGAATGG
408


ID

burgdorferi





AGCGGITCTGGAAY









ACTTGAAGG











ospA_UT1_F2
ACCCAACTGAATGG
409








AGCGGATCTGGRRT









RCTTGAAGG











ospA_UT1_F3
ACCCAACTGAATGG
410








AGCGGTTCTGGAAS









CCTTGARGG











ospA_UT1_F4
ACCCAACTGAATGG
411








AGCGGRYCTGGGG









TRCTTGAAGG











ospA_UT1_F5
ACCCAACTGAATGG
412








AGCGGATCTGGGG









GAAAGCTTGAAG











ospA_UT1_F6
ACCCAACTGAATGG
413








AGCGGTTCTGGDGT









RCTKGAAGG











ospA_UT1_F7
ACCCAACTGAATGG
414








AGCGGATCTGGMW









HGCYYGAAGG











ospA_UT1_F8
ACCCAACTGAATGG
415








AGCGGMGCTGGAM









AWCTTGAAGG











ospA_UT1_R1
ACGCACTTGACTTG
416








TCTTCCAAGTYTGK









TKCCRTTTKCTCTT









G











ospA_UT1_R2
ACGCACTTGACTTG
417








TCTTCCAAGYYTGG









TWCCGTYTGCTCTT









R











ospA_UT1_R3
ACGCACTTGACTTG
418








TCTTCCMAGTGTAG









TYCCGYTTGDTCTT









G











ospA_UT1_R4
ACGCACTTGACTTG
419








TCTTCCAAGTMTKG









WWCCRTTTGCTCTT









R











ospA_UT1_R5
ACGCACTTGACTTG
420








TCTTCCAAGKGTAG









TTTCGTTTKCTCTTG











ospA_UT1_R6
ACGCACTTGACTTG
421








TCTTCCAAKTGTAG









TATYRTTTGATCTT









G











ospA_UT1_R7
ACGCACTTGACTTG
422








TCTTCCAAGMKTRG









TKCCGTTTGCTCTT









G











ospA_UT1_R8
ACGCACTTGACTTG
423








TCTTCCAAGTCTGG









TTCCGTCTTTTCTTG











ospA_UT1_R9
ACGCACTTGACTTG
424








TCTTCCAAGTGGTG









TTCCGTTTGTTCTTG











ospA_UT1_R1
ACGCACTTGACTTG
425







0
TCTTCCAAGTCTAT









TTCCATTTGCTCTT









G











ospA_UT1_R1
ACGCACTTGACTTG
426







1
TCTTCCAAGTCTGG









TTCCGTTAYCTCTT









A











ospA_UT1_R1
ACGCACTTGACTTG
427







2
TCTTCCAAGTCTGG









TTCCATTTGCCCTT









A






Species

Borrelia

porin gene
presence/
p66-
p66_UT2_F
ACCCAACTGAATGG
428


ID

burgdorferi


absence
borrelia_UT2

AGCTGTAATTGCAG









AAACACCTTTTGA











p66_UT2_R
ACGCACTTGACTTG
429








TCTTCGCTGCTTTT









GAGATGTGTCC






Genus

Bartonella

ssrA
presence/
Bart-
Bart-
ACCCAACTGAATGG
430


ID


absence
ssrA_UT1
ssrA_UT1_F
AGCGGCTAAATIAG









TAGTTGCAAAYGAC









A











Bart-
ACGCACTTGACTTG
431







ssrA_UT1_R
TCTTCGCTTCTGTT









GCCAGGTG






Genus

Babesia

18S
sequence-
Babe-
Babe-
ACCCAACTGAATGG
432


ID


based
188_UT1
18S_UT1_F
AGCACCGTCCAAA









GCTGATAGGTC











Babe-
ACGCACTTGACTTG
433







18S_UT1_R
TCTTCCGAAACTGC









GAATGGCTCATTA






Genus

Rickettsia

ompA
presence/
Rkttsia-
Rkttsia-
ACCCAACTGAATGG
434


ID


absence
ompA_UT1
ompA_UT1_F
AGCGGCATTTACTT









ACRGTGSTGAT











Rkttsia-
ACGCACTTGACTTG
435







ompA_UT1_R
TCTTCCCATGATTT









GCAGCAAYAGCAT










Rkttsia-
Rkttsia-
ACCCAACTGAATGG
436






ompA_UT2
ompA_UT2_F
AGCCGYTAGCTGG









GCTTAGRTATTC











Rkttsia-
ACGCACTTGACTTG
437







ompA_UT2_R
TCTTCCGCCGRAAC









TTTATTCTTGAATG










Rkttsia-
Rkttsia-
ACCCAACTGAATGG
438






ompA_UT3
ompA_UT3_F
AGCACTTAYGGTGG









TGATTATAYTATC











Rkttsia-
ACGCACTTGACTTG
439







ompA_UT3_R
TCTTCTGCAGCAAC









AGCATTAKTACYG










Rkttsia-
Rkttsia-
ACCCAACTGAATGG
440






ompA_UT4
ompA_UT4_F
AGCGCTGRAGGAG








1
TAGCTAATGGT











Rkttsia-
ACCCAACTGAATGG
441







ompA_UT4_F
AGCGCAGCAGGAG








2
TAGCTGATGAT











Rkttsia-
ACGCACTTGACTTG
442







ompA_UT4_R
TCTTCMCGCAGCAG









TACCGGTTAAAG










Rkttsia-
Rkttsia-
ACCCAACTGAATGG
443






ompA_UT5
ompA_UT5_F
AGCCAACCGCAGC









RWTAATGCTAAC











Rkttsia-
ACGCACTTGACTTG
444







ompA_UTS_R
TCTTCCCTCCCGTA









TCTACCACTGAAC










Rkttsia-
Rkttsia-
ACCCAACTGAATGG
445






ompA_UT6
ompA_UT6_F
AGCTGCAGGAGCA









GATAATGGTA











Rkttsia-
ACGCACTTGACTTG
446







ompA_UT6_R
TCTTCGCCGGCAGT









AATAGTAACAG










Rkttsia-
Rkttsia-
ACCCAACTGAATGG
447






ompA_UT7
ompA_UT7_F
AGCGGTGCAAGCC








1
AAGTAACATATAC











Rkttsia-
ACCCAACTGAATGG
448







ompA_UT7_F
AGCAGGTACAAAT








2
CAAGTAACATATAC









C











Rkttsia-
ACGCACTTGACTTG
449







ompA_UT7_R
TCTTCAAACCGCCT








1
TCCGTTTCTG











Rkttsia-
ACGCACTTGACTTG
450







ompA_UT7_R
TCTTCAATCCACCT








2
GCCGCTTCTG






Genus
Powassan

presence/
Powass_UT
Powass_UT_F
ACCCAACTGAATGG
451


ID
and deer

absence

I
AGCGGCDGTAGGY




tick viruses




CATGTTTATGAC











Powass_UT_F
ACCCAACTGAATGG
452







2
AGCAGCTGTGGGCC









ACGTCTATGAC











Powass_UT_R
ACGCACTTGACTTG
453







1
TCTTCCCGAAGGCA









GGTGATCTTTG











Powass_UT_R
ACGCACTTGACTTG
454







2
TCTTCCAGAAGGCA









GGTGGTCCTTG






Internal
Human
gapDH
presence/
IPC-
IPC-
ACCCAACTGAATGG
455


control


absence
gapDH_UT1
gapDH_UT1
AGCCCTGCCAAATA








F
TGATGACATCAAG











IPC-
ACGCACTTGACTTG
456







gapDH_UT1
TCTTCGTGGTCGTT








R
GAGGGCAATG






Differen-
Enterovirus
VP1
presence/
EV-D68_UT
EV-
ACCCAACTGAATGG
457


tial
strain D68

absence

D68_UT_F1
AGCACCAGARGAA



diagnos-





GCCATACAAAC



tics

















EV-
ACCCAACTGAATGG
458







D68_UT_F2
AGCTGACACTTCAA









GCAATGTTCGTA











EV-
ACCCAACTGAATGG
459







D68_UT_F3
AGCAACGCCGAAC









TTGGTGTG











EV-
ACCCAACTGAATGG
460







D68_UT_F4
AGCAACACCGAAC









CAGAGGAAG











EV-
ACGCACTTGACTTG
461







D68_UT_R1
TCTTCTGACACTTC









AAGCAATGTTCGTA











EV-
ACGCACTTGACTTG
462







D68_UT_R2
TCTTCAACGCCGAA









CTTGGTGTG











EV-
ACGCACTTGACTTG
463







D68_UT_R3
TCTTCAACACCGAA









CCAGAGGAAG











EV-
ACGCACTTGACTTG
464







D68_UT_R4
TCTTCSCTGAYTGC









CARTGGAATGAA











EV-
ACGCACTTGACTTG
465







D68_UT_R5
TCTTCATGTGCTGT









TATTGCTACCTACT









G






Differen-

Staphylococcus



Sa_M4_UT2
Sa_M4_UT2
ACCCAACTGAATGG
466


tial

aureus




F
AGCTAGCGTTGGTA



diagnos-





TTAAGTGGTTGT



tics

















Sa_M4_UT2
ACGCACTTGACTTG
467







R
TCTTCTCAAATCCA









GCAAAGCCATCA






Differen-
Influenza A
matrix gene
presence/
H3N2_UT
H3N2_UT_F
ACCCAACTGAATGG
468


tial


absence


AGCAAGACCAATY



diagnos-





CTGTCACCTCTGA



tics















RNA target

H3N2_UT_R
ACGCACTTGACTTG
469








TCTTCTAGCGTTGG









TATTAAGTGGTTGT






Differen-

Yersinia

plasmid

Yppla_UT
Yppla_UT_F
ACCCAACTGAATGG
470


tial

pestis





AGCGAAAGGAGTG



diagnos-





CGGGTAATAGGTT



tics

















Yppla_UT_R
ACGCACTTGACTTG
471








TCTTCAAGACCAAT









YCTGTCACCTCTGA








chromosome

Yp3a_UT
Yp3a_UT_F
ACCCAACTGAATGG
472








AGCCATTGGACGGC









ATCACGAT











Yp3a_UT_R
ACGCACTTGACTTG
473








TCTTCGAAAGGAGT









GCGGGTAATAGGTT






Differen-

Francisclla


SNP
Ft-G_UT
Ft-G_UT_F
ACCCAACTGAATGG
474


tial

tularemis





AGCCTAAGCCATAA



diagnos-





GCCCTTTCTCTAAC



tics





TTGT











Ft-G_UT_R
ACGCACTTGACTTG
475








TCTTCCATTGGACG









GCATCACGAT








Claims
  • 1. A kit for detection of at least one Borrelia species causing Lyme Disease or tick-borne relapsing fever (TBRF), the kit comprising: primer pairs targeting at least one region of Borrelia 16S rRNA and at least one region of flaB, ospA, ospB, ospC, glpQ, 16S-23S intergenic spacer (IGS1), 5S-23S intergenic spacer (IGS2), bbk32, dbpA, dbpB, and/or p66.
  • 2. The kit of claim 1, wherein primer pairs targeting the least one region of Borrelia 16S rRNA comprises sequences selected from the group consisting of: SEQ ID NOS: 1-10.
  • 3. The kit of claim 2, wherein the primer pairs targeting at least one region of flaB, ospA, ospB, ospC, glpQ, 16S-23S intergenic spacer (IGS), 5S-23S intergenic spacer (IGS2), bbk32, dbpA, dbpB, and/or p66 contain sequences selected from the group consisting of SEQ ID NOS: 11-48, SEQ ID NOS: 60-77, SEQ ID NOS: 97-100, and SEQ ID NOS: 219-293.
  • 4. The kit of claim 3, further comprises primer pairs containing sequences selected from the group consisting of SEQ ID NOS: 49-59, SEQ ID NOS: 78-96, SEQ ID NOS: 105-108, and SEQ ID NOS: 294-314.
  • 5. The kit of claim 4, further comprising a nucleotide polymerase, buffer, diluent, and/or excipien one or more primers comprising a sequence selected from SEQ ID NOS: 109 and 110 for amplifying human GAPDH as an internal control.
  • 6. The kit of claim 1, wherein the primer pairs are labeled
  • 7. The kit of claim 6, wherein the labeled primer pairs comprise a universal tail sequence.
  • 8. The kit of claim 6, wherein the labeled primer pairs comprise chain termination bases is labeled with a fluorescent label of a different wavelength that allows the sequencing to be performed in a single reaction.
  • 9. A kit for detecting one or more Borrelia species causing Lyme Disease or tick-borne relapsing fever (TBRF) within a sample from a subject, the kit comprising: a) primers targeting: at least one region of Borrelia 16S rRNA;at least one region of a 16S-23S intergenic spacer (IGS1);at least one region of a 5S-23S intergenic spacer (IGS2);at least one region of a flagella subunit B (flaB) gene;at least one region of a bbk32 gene;at least one region of a dbpA gene;at least one region of a dbpB gene;at least one region of an ospA geneat least one region of an ospB gene;at least one region of an ospC gene;at least one region of a p66 porin gene; andat least one region of a glpQ gene.
  • 10. The kit of claim 9, wherein the at least one region of Borrelia 16S rRNA contain sequences selected from the group consisting of: SEQ ID NOS: 1-10.
  • 11. The kit of claim 10, wherein: the at least one region of the 16S-23 S intergenic spacer (IGS1) contains sequences selected from the group consisting of SEQ ID NOS: 17-20 and 219-232;the at least one region of the 5S-23S intergenic spacer (IGS2) contains sequences selected from the group consisting of SEQ ID NOS: 11-16;the at least one region of the flagella subunit B (flaB) gene contains sequences selected from the group consisting of SEQ ID NOS: 21-29;the at least one region of the bbk32 gene contains sequences selected from the group consisting of SEQ ID NOS: 41-44;the at least one region of the dbpA gene contains sequences selected from the group consisting of SEQ ID NOS: 45-46 and 233-239;the at least one region of the dbpB gene contains sequences selected from the group consisting of SEQ ID NOS: 47-48 and 240-248;the at least one region of the ospA gene contains sequences selected from the group consisting of SEQ ID NOS: 274-293;the at least one region of the ospB gene contains sequences selected from the group consisting of SEQ ID NOS: 60-63 and 249-261;the at least one region of the ospC gene contains sequences selected from the group consisting of SEQ ID NOS: 64-69 and 262-263;the at least one region of the p66 porin gene contains sequences selected from the group consisting of SEQ ID NOS: 70-75 and 264-273; andthe at least one region of the glpQ gene contains sequences selected from the group consisting of SEQ ID NOS: 30-40.
  • 12. The method of claim 9, wherein the amplification products are analyzed by size determination with agarose gel electrophoresis.
  • 13. The kit of claim 9, wherein the primer pairs comprise a universal tail sequence.
  • 14. The kit of claim 9, wherein the one or more Borrelia species are selected from the group consisting of: Borrelia afzelii, Borrelia americana, Borrelia andersonii, Borrelia anserina, Borrelia baltazardii, Borrelia bavariensis, Borrelia bissettii, Borrelia brasiliensis, Borrelia burgdorferi, Borrelia californiensis, Borrelia carolinensis, Borrelia caucasica, Borrelia coriaceae, Borrelia crocidurae, Borrelia dugesii, Borrelia duttonii, Borrelia garinii, Borrelia graingeri, Borrelia harveyi, Borrelia hermsii, Borrelia hispanica, Borrelia japonica, Borrelia kurtenbachii, Borrelia latyschewii, Borrelia lonestari, Borrelia lusitaniae, Borrelia mayonii, Borrelia mazzottii, Borrelia merionesi, Borrelia microti, Borrelia miyamotoi, Borrelia parkeri, Borrelia persica, Borrelia queenslandica, Borrelia recurrentis, Borrelia sinica, Borrelia spielmanii, Borrelia tanukii, Borrelia theileri, Borrelia tillae, Borrelia turcica, Borrelia turdi, Borrelia turicatae, Borrelia valaisiana, Borrelia venezuelensis, Borrelia vincentii, and Candidatus Borrelia texasensis.
  • 15. The kit of claim 9, wherein the one or more Borrelia species are selected from the group consisting of: Borrelia burgdorferi, Borrelia garinii, Borrelia mayonii, and Borrelia afzelii.
  • 16. The kit of claim 9, further comprising detecting in the sample a Babesia species, an Ehrlichia species, a Bartonella species, Francisella tularensis, Yersinia pestis, Staphylococcus aureus, Anaplasma phagocytophilum, Enterovirus, Powassan and deer tick virus, Rickettsia species, and/or Influenza by subjecting the DNA and/or RNA from the sample to a second PCR amplification reaction using primer pairs containing sequences selected from the group consisting of: SEQ ID NOS: 49-55 for detection of Anaplasma phagocytophilum; SEQ ID NOS: 56-59 for detection of an Ehrlichia species;SEQ ID NOS: 78-86 for detection of Enterovirus;SEQ ID NOS: 87-88 for detection of Staphylococcus aureus; SEQ ID NOS: 89-90 for detection of Influenza;SEQ ID NOS: 91-94 for detection of Yersinia pestis; SEQ ID NOS: 95-96 for detection of Francisella tularensis; SEQ ID NOS: 105-106 for detection of a Bartonella species;SEQ ID NOS: 107-108 for detection of a Babesia species;SEQ ID NOS: 294-310 for detection of a Rickettsia species; andSEQ ID NOS: 311-314 for detection of a Powassan and deer tick virus.
  • 17. The kit of claim 9, further comprises a nucleotide polymerase, buffer, diluent, and/or excipient; one or more primers comprising a sequence selected from SEQ ID NOS: 109 and 110 for amplifying human GAPDH as an internal control; and the primer pairs are labeled
  • 18. A method of detecting one or more Borrelia species causing Lyme Disease or tick-borne relapsing fever (TBRF) within a sample from a subject, the method comprising: a) subjecting DNA and/or RNA from the sample to a multiplex PCR amplification reaction with primers targeting: at least one region of Borrelia 16S rRNA;at least one region of a 16S-23S intergenic spacer (IGS1);at least one region of a 5S-23S intergenic spacer (IGS2);at least one region of a flagella subunit B (flaB) gene;at least one region of a bbk32 gene;at least one region of a dbpA gene;at least one region of a dbpB gene;at least one region of an ospA geneat least one region of an ospB gene;at least one region of an ospC gene;at least one region of a p66 porin gene; andat least one region of a glpQ gene; andb) analyzing amplification products resulting from the PCR amplification reaction to detect the one or more Borrelia species.
  • 19. The method of claim 18, wherein the amplification products are analyzed to determine the sequence of each amplification product.
  • 20. The method of claim 18, wherein the sequence of each amplification product is mapped to a reference library of known Borrelia sequences to detect the one or more Borrelia species and to identify Borrelia species that cause Lyme Disease and Borrelia species that do not cause Lyme Disease.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a Divisional of U.S. patent application Ser. No. 16/076,608, filed Aug. 8, 2018 (published as US20190040455), which is the U.S. National Stage of International Patent Application No. PCT/US2017/017573, filed Feb. 11, 2017, which claims priority to U.S. Provisional Patent Application No. 62/293,873, filed Feb. 11, 2016, the contents of which are incorporated herein by reference in their entirety.

Provisional Applications (1)
Number Date Country
62293873 Feb 2016 US
Divisions (1)
Number Date Country
Parent 16076608 Aug 2018 US
Child 17745832 US